title: Variants of SARS-CoV-2

abstract: Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are of enough significance to lead virologists to label them separately. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Some have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic. As of 24 September 2024, the variants of interest as specified by the World Health Organization are BA.2.86 and JN.1, and the variants under monitoring are JN.1.7, KP.2, KP.3, KP.3.1.1, JN.1.18, LB.1, and XEC.

text:
# Variants of SARS-CoV-2

**Variants of severe acute respiratory syndrome coronavirus 2** (SARS-CoV-2) are viruses that, while similar to the original, have genetic changes that are of enough significance to lead virologists to label them separately. SARS-CoV-2 is the virus that causes coronavirus disease 2019 (COVID-19). Some have been stated, to be of particular importance due to their potential for increased transmissibility, increased virulence, or reduced effectiveness of vaccines against them. These variants contribute to the continuation of the COVID-19 pandemic.

As of 24 September 2024, the variants of interest as specified by the World Health Organization are BA.2.86 and JN.1, and the variants under monitoring are JN.1.7, KP.2, KP.3, KP.3.1.1, JN.1.18, LB.1, and XEC.

## Overview

The origin of SARS-CoV-2 has not been identified. However, the emergence of SARS-CoV-2 may have resulted from recombination events between a bat SARS-like coronavirus and a pangolin coronavirus through cross-species transmission. The earliest available SARS-CoV-2 viral genomes were collected from patients in December 2019, and Chinese researchers compared these early genomes with bat and pangolin coronavirus strains to estimate the ancestral human coronavirus type; the identified ancestral genome type was labeled "S", and its dominant derived type was labeled "L" to reflect the mutant amino acid changes. Independently, Western researchers carried out similar analyses but labeled the ancestral type "A" and the derived type "B". The B-type mutated into further types including B.1, which is the ancestor of the major global variants of concern, labeled in 2021 by the WHO as alpha, beta, gamma, delta and omicron variants.

Early in the pandemic, the relatively low number of infections (compared with later stages of the pandemic) resulted in fewer opportunities for mutation of the viral genome and, therefore, fewer opportunities for the occurrence of differentiated variants. Since the occurrence of variants was rarer, the observation of S-protein mutations in the receptor-binding domain (RBD) region interacting with ACE2 was also not frequent.

As time went on, the evolution of SARS-CoV-2's genome (by means of random mutations) led to mutant specimens of the virus (i.e., genetic variants), observed to be more transmissible, to be naturally selected. Notably, both the Alpha and the Delta variants were observed to be more transmissible than previously identified viral strains.

Some SARS-CoV-2 variants are considered to be of concern as they maintain (or even increase) their replication fitness in the face of rising population immunity, either by infection recovery or via vaccination. Some of the variants of concern show mutations in the RBD of the S-protein.

## Definitions

The term **variant of concern** (**VOC**) for SARS-CoV-2, which causes COVID-19, is a category used for variants of the virus where mutations in their spike protein receptor binding domain (RBD) substantially increase binding affinity (e.g., N501Y) in RBD-hACE2 complex (genetic data), while also being linked to rapid spread in human populations (epidemiological data).

Before being allocated to this category, an emerging variant may have been labeled a **variant of interest** (**VOI**), or in some countries a **variant under investigation** (**VUI**). During or after fuller assessment as a variant of concern the variant is typically assigned to a lineage in the Pango nomenclature system and to clades in the Nextstrain and GISAID systems.

Historically, the WHO regularly listed updates on variants of concern (VOC), which are variants with an increased rate of transmission, virulence, or resistance against mitigations, like vaccines. The variant submissions from member states are then submitted to GISAID, followed by field investigations of the variant. Updated definitions, published on the 4 October 2023, add variants of interest (VOI) and variants under monitoring (VUM) to the World Health Organization's working definitions for SARS-CoV-2 variants. Other organisations such as the CDC in the United States typically define their variants of concern slightly differently; for example, the CDC de-escalated the Delta variant on 14 April 2022, while the WHO did so on 7 June 2022.

As of 15 March 2023, The WHO defines a VOI as a variant "with genetic changes that are predicted or known to affect virus characteristics such as transmissibility, virulence, antibody evasion, susceptibility to therapeutics and detectability" and that is circulating more than other variants in over one WHO region to such an extent that a global public health risk can be suggested. Furthermore, the update stated that "VOIs will be referred to using established scientific nomenclature systems such as those used by Nextstrain and Pango".

## Notability criteria

Viruses generally acquire mutations over time, giving rise to new variants. When a new variant appears to be growing in a population, it can be labelled as an "emerging variant". In the case of SARS-CoV-2, new lineages often differ from one another by just a few nucleotides.

Some of the potential consequences of emerging variants are the following:

* Increased transmissibility
* Increased morbidity
* Increased mortality
* Ability to evade detection by diagnostic tests
* Decreased susceptibility to antiviral drugs (if and when such drugs are available)
* Decreased susceptibility to neutralising antibodies, either therapeutic (e.g., convalescent plasma or monoclonal antibodies) or in laboratory experiments
* Ability to evade natural immunity (e.g., causing reinfections)
* Ability to infect vaccinated individuals
* Increased risk of particular conditions such as multisystem inflammatory syndrome or long COVID.
* Increased affinity for particular demographic or clinical groups, such as children or immunocompromised individuals.

Variants that appear to meet one or more of these criteria may be labelled **"variants under investigation"** or **"variants of interest"** pending verification and validation of these properties. The primary characteristic of a variant of interest is that it shows evidence that demonstrates it is the cause of an increased proportion of cases or unique outbreak clusters; however, it must also have limited prevalence or expansion at national levels, or the classification would be elevated to a "variant of concern". If there is clear evidence that the effectiveness of prevention or intervention measures for a particular variant is substantially reduced, that variant is termed a "variant of high consequence".

## Nomenclature

SARS-CoV-2 corresponding nomenclatures
| PANGO lineages | Notes to PANGO lineages | Nextstrain clades, 2021 | GISAID clades | Notable variants |
| --- | --- | --- | --- | --- |
| A.1–A.6 |  | 19B | S | Contains "reference sequence" WIV04/2019 |
| B.3–B.7, B.9, B.10, B.13–B.16 |  | 19A | L |  |
| | | | O |  |
| B.2 |  | | V |  |
| B.1 | B.1.5–B.1.72 | 20A | G | Lineage B.1 in the PANGO Lineages nomenclature system; includes Delta/B.1.617 |
| | B.1.9, B.1.13, B.1.22, B.1.26, B.1.37 | | GH |  |
| | | B.1.3–B.1.66 | 20C | Includes Epsilon/B.1.427/B.1.429/CAL.20C and Eta/B.1.525 |
| | | 20G | Predominant in US generally, Feb '21 |
| | | 20H | Includes Beta/B.1.351 aka 20H/501Y.V2 or 501.V2 lineage |
| |
| | B.1.1 | 20B | GR | Includes B.1.1.207 and Lambda (lineage C.37) |
| | 20D | |  |
| | 20J | | Includes Gamma/P.1 and Zeta/P.2 |
| | 20F | |  |
| | 20I | | Includes Alpha/B.1.1.7 aka VOC-202012/01, VOC-20DEC-01 or 20I/501Y.V1 |
| B.1.177 | 20E (EU1) | GV | Derived from 20A |
|

SARS-CoV-2 variants are grouped according to their lineage and component mutations. Many organisations, including governments and news outlets, referred colloquially to concerning variants by the country in which they were first identified. After months of discussions, the World Health Organization announced Greek-letter names for important strains on 31 May 2021, so they could be easily referred to in a simple, easy to say, and non-stigmatising fashion. This decision may have partially been taken because of criticism from governments on using country names to refer to variants of the virus; the WHO mentioned the potential for mentioning country names to cause stigma. After using all the letters from Alpha to Mu (see below), in November 2021 the WHO skipped the next two letters of the Greek alphabet, Nu and Xi, and used Omicron, prompting speculation that Xi was skipped to avoid offending Chinese leader Xi Jinping. The WHO gave as the explanation that Nu is too easily confounded with "new" and Xi is a common last name. In the event that the WHO uses the entirety of the Greek alphabet, the agency considered naming future variants after constellations.

### Lineages and clades

While there are many thousands of variants of SARS-CoV-2, subtypes of the virus can be put into larger groupings such as lineages or clades. Three main, generally used nomenclatures have been proposed:

* As of January 2021, GISAID—referring to SARS-CoV-2 as hCoV-19—had identified eight global clades (S, O, L, V, G, GH, GR, and GV).
* In 2017, Hadfield et al. announced Nextstrain, intended "for real-time tracking of pathogen evolution". Nextstrain has later been used for tracking SARS-CoV-2, identifying 13 major clades (19A–B, 20A–20J and 21A) as of June 2021.
* In 2020, Rambaut et al. of the Phylogenetic Assignment of Named Global Outbreak Lineages (PANGOLIN) software team proposed in an article "a dynamic nomenclature for SARS-CoV-2 lineages that focuses on actively circulating virus lineages and those that spread to new locations"; as of August 2021, 1340 lineages had been designated.

Each national public health institute may also institute its own nomenclature system for the purposes of tracking specific variants. For example, Public Health England designated each tracked variant by year, month and number in the format \[YYYY\] \[MM\]/\[NN\], prefixing 'VUI' or 'VOC' for a variant under investigation or a variant of concern respectively. This system has now been modified and now uses the format \[YY\] \[MMM\]-\[NN\], where the month is written out using a three-letter code.

## Reference sequence

As it is currently not known when the index case or "patient zero" occurred, the choice of reference sequence for a given study is relatively arbitrary, with different notable research studies' choices varying as follows:

* The earliest sequence, *Wuhan-1*, was collected on 24 December 2019.
* One group (Sudhir Kumar et al.) refers extensively to an NCBI reference genome (GenBankID:NC\_045512; GISAID ID: EPI\_ISL\_402125), this sample was collected on 26 December 2019, although they also used the *WIV04* GISAID reference genome (ID: EPI\_ISL\_402124), in their analyses.
* According to another source (Zhukova et al.), the sequence *WIV04/2019*, belonging to the GISAID S clade / PANGO A lineage / Nextstrain 19B clade, is thought to most closely reflect the sequence of the original virus infecting humans—known as "sequence zero". *WIV04/2019* was sampled from a symptomatic patient on 30 December 2019 and is widely used (especially by those collaborating with GISAID) as a reference sequence.

The variant first sampled and identified in Wuhan, China is considered by researchers to differ from the progenitor genome by three mutations. Subsequently, many distinct lineages of SARS-CoV-2 have evolved.

## Overview of historical variants of concern or under monitoring

The following table presents information and relative risk level for currently and formerly circulating variants of concern (VOC). The intervals assume a 95% confidence or credibility level, unless otherwise stated. Currently, all estimates are approximations due to the limited availability of data for studies. For Alpha, Beta, Gamma and Delta, there is no change in test accuracy, and neutralising antibody activity is retained by some monoclonal antibodies. PCR tests continue to detect the Omicron variant.

Variants of SARS-CoV-2 table
| Identification | | | Emergence | | | | Changes relative to previously circulating variants at the time and place of emergence | | | | Neutralising antibody activity (or efficacy when available) | |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| WHO
label | PANGO
lineage | Nextstrain
clade | First
outbreak | Earliest
sample | Designated VOC | Current circulation | Notable mutations | Transmissibility | Hospitalisation | Mortality | From natural infection | From vaccination |
| Delta | B.1.617.2 | 21A | India | Oct 2020 | 6 May 2021 | No | L452R, T478K, P681R | +97% (76117%) | +85% (39147%) relative to Alpha | +137% (50230%) | Reinfections happened, with smaller occurrence rate than vaccinated infections | Efficacy reduction for non-severe disease |
| Omicron | B.1.1.529 | 21K | South Africa | 9 Nov 2021 | 26 Nov 2021 | Yes | P681H, N440K, N501Y, S477N, many others | Possibly increased | −57% (5961%) relative to Delta | −63% (6974%) relative to Delta | Increased reinfection rate | Efficacy reduction against symptomatic disease, unknown for severe disease |
| Alpha | B.1.1.7 | 20I (V1) | United Kingdom | 20 Sep 2020 | 18 Dec 2020 | No | 69–70del, N501Y, P681H | +29% (2433%) | +52% (4757%) | +59% (4474%) | Minimal reduction | Minimal reduction |
| Gamma | P.1 (B.1.1.28.1) | 20J (V3) | Brazil | Nov 2020 | 15 Jan 2021 | No | K417T, E484K, N501Y | +38% (2948%) | Possibly increased | +50% (50% CrI, 2090%) | Reduced | Retained by many |
| Beta | B.1.351 | 20H (V2) | South Africa | May 2020 | 14 Jan 2021 | No | K417N, E484K, N501Y | +25% (2030%) | *Under investigation* | Possibly increased | Reduced, T cell response elicited by D614G virus remains effective | Efficacy reduction against symptomatic disease, retained against severe disease |
| Very high risk   High risk   Medium risk   Low risk   Unknown risk | | | | | | | | | | | | |

## Previously circulating and formerly monitored variants (WHO)

The WHO defines a previously circulating variant as a variant that "has demonstrated to no longer pose a major added risk to global public health compared to other circulating SARS-CoV-2 variants", but should still be monitored.

On 15 March 2023, the WHO released an update on the tracking system of VOCs, announcing that only VOCs will be assigned Greek letters.

### Previously circulating variants of concern (VOC)

The variants listed below had previously been designated as variants of concern, but were displaced by other variants. As of May 2022, the WHO lists the following under "previously circulating variants of concern":

#### Alpha (lineage B.1.1.7)

First detected in October 2020 during the COVID-19 pandemic in the United Kingdom from a sample taken the previous month in Kent, lineage B.1.1.7, labelled Alpha variant by the WHO, was previously known as the first Variant Under Investigation in December 2020 (VUI – 202012/01) and later notated as VOC-202012/01. It is also known as 20I (V1), 20I/501Y.V1 (formerly 20B/501Y.V1), or 501Y.V1. From October to December 2020, its prevalence doubled every 6.5 days, the presumed generational interval. It is correlated with a significant increase in the rate of COVID-19 infection in United Kingdom, associated partly with the N501Y mutation. There was some evidence that this variant had 40–80% increased transmissibility (with most estimates lying around the middle to higher end of this range), and early analyses suggested an increase in lethality, though later work found no evidence of increased virulence. As of May 2021, the Alpha variant had been detected in some 120 countries.

On 16 March 2022, the WHO has de-escalated the Alpha variant and its subvariants to "previously circulating variants of concern".

##### B.1.1.7 with E484K

Variant of Concern 21FEB-02 (previously written as VOC-202102/02), described by Public Health England (PHE) as "B.1.1.7 with E484K" is of the same lineage in the Pango nomenclature system, but has an additional E484K mutation. As of 17 March 2021, there were 39 confirmed cases of VOC-21FEB-02 in the UK. On 4 March 2021, scientists reported B.1.1.7 with E484K mutations in the state of Oregon. In 13 test samples analysed, one had this combination, which appeared to have arisen spontaneously and locally, rather than being imported. Other names for this variant include B.1.1.7+E484K and B.1.1.7 Lineage with S:E484K.

#### Beta (lineage B.1.351)

On 18 December 2020, the 501.V2 variant, also known as 501.V2, 20H (V2), 20H/501Y.V2 (formerly 20C/501Y.V2), 501Y.V2, VOC-20DEC-02 (formerly VOC-202012/02), or lineage B.1.351, was first detected in South Africa and reported by the country's health department. It has been labelled as Beta variant by WHO. Researchers and officials reported that the prevalence of the variant was higher among young people with no underlying health conditions, and by comparison with other variants it is more frequently resulting in serious illness in those cases. The South African health department also indicated that the variant may be driving the second wave of the COVID-19 epidemic in the country due to the variant spreading at a more rapid pace than other earlier variants of the virus.

Scientists noted that the variant contains several mutations that allow it to attach more easily to human cells because of the following three mutations in the receptor-binding domain (RBD) in the spike glycoprotein of the virus: N501Y, K417N, and E484K. The N501Y mutation has also been detected in the United Kingdom.

On 16 March 2022, the WHO has de-escalated the Beta variant and its subvariants to "previously circulating variants of concern".

#### Gamma (lineage P.1)

The Gamma variant or lineage P.1, termed Variant of Concern 21JAN-02 (formerly VOC-202101/02) by Public Health England, 20J (V3) or 20J/501Y.V3 by Nextstrain, or just 501Y.V3, was detected in Tokyo on 6 January 2021 by the National Institute of Infectious Diseases (NIID). It has been labelled as Gamma variant by WHO. The new variant was first identified in four people who arrived in Tokyo having travelled from the Brazilian Amazonas state on 2 January 2021. On 12 January 2021, the Brazil-UK CADDE Centre confirmed 13 local cases of the new Gamma variant in the Amazon rainforest. This variant of SARS-CoV-2 has been named lineage P.1 (although it is a descendant of B.1.1.28, the name B.1.1.28.1 is not permitted and thus the resultant name is P.1), and has 17 unique amino acid changes, 10 of which in its spike protein, including the three concerning mutations: N501Y, E484K and K417T.

The N501Y and E484K mutations favour the formation of a stable RBD-hACE2 complex, thus, enhancing the binding affinity of RBD to hACE2. However, the K417T mutation disfavours complex formation between RBD and hACE2, which has been demonstrated to reduce the binding affinity.

The new variant was absent in samples collected from March to November 2020 in Manaus, Amazonas state, but it was detected for the same city in 42% of the samples from 15 to 23 December 2020, followed by 52.2% during 15–31 December and 85.4% during 1–9 January 2021. A study found that infections by Gamma can produce nearly ten times more viral load compared to persons infected by one of the other lineages identified in Brazil (B.1.1.28 or B.1.195). Gamma also showed 2.2 times higher transmissibility with the same ability to infect both adults and older persons, suggesting P.1 and P.1-like lineages are more successful at infecting younger humans irrespective of sex.

A study of samples collected in Manaus between November 2020 and January 2021, indicated that the Gamma variant is 1.4–2.2 times more transmissible and was shown to be capable of evading 25–61% of inherited immunity from previous coronavirus diseases, leading to the possibility of reinfection after recovery from an earlier COVID-19 infection. As for the fatality ratio, infections by Gamma were also found to be 10–80% more lethal.

A study found that people fully vaccinated with Pfizer or Moderna have significantly decreased neutralisation effect against Gamma, although the actual impact on the course of the disease is uncertain. A pre-print study by the Oswaldo Cruz Foundation published in early April found that the real-world performance of people with the initial dose of the Sinovac's Coronavac Vaccine had approximately 50% efficacy rate. They expected the efficacy to be higher after the 2nd dose. As of July 2021, the study is ongoing.

Preliminary data from two studies indicate that the Oxford–AstraZeneca vaccine is effective against the Gamma variant, although the exact level of efficacy has not yet been released. Preliminary data from a study conducted by Instituto Butantan suggest that CoronaVac is effective against the Gamma variant as well, and as of July 2021 has yet to be expanded to obtain definitive data.

On 16 March 2022, the WHO has de-escalated the Gamma variant and its subvariants to "previously circulating variants of concern".

#### Delta (lineage B.1.617.2)

The Delta variant, also known as B.1.617.2, G/452R.V3, 21A or 21A/S:478K, was a globally dominant variant that spread to at least 185 countries. It was first discovered in India. Descendant of lineage B.1.617, which also includes the Kappa variant under investigation, it was first discovered in October 2020 and has since spread internationally. On 6 May 2021, British scientists declared B.1.617.2 (which notably lacks mutation at E484Q) as a "variant of concern", labelling it VOC-21APR-02, after they flagged evidence that it spreads more quickly than the original version of the virus and could spread quicker or as quickly as Alpha. It carries L452R and P681R mutations in Spike; unlike Kappa it carries T478K but not E484Q.

On 3 June 2021, Public Health England reported that twelve of the 42 deaths from the Delta variant in England were among the fully vaccinated, and that it was spreading almost twice as fast as the Alpha variant. Also on 11 June, Foothills Medical Centre in Calgary, Canada reported that half of their 22 cases of the Delta variant occurred among the fully vaccinated.

In June 2021, reports began to appear of a variant of Delta with the K417N mutation. The mutation, also present in the Beta and Gamma variants, raised concerns about the possibility of reduced effectiveness of vaccines and antibody treatments and increased risk of reinfection. The variant, called "Delta with K417N" by Public Health England, includes two clades corresponding to the Pango lineages AY.1 and AY.2. It has been nicknamed "Delta plus" from "Delta plus K417N". The name of the mutation, K417N, refers to an exchange whereby lysine (K) is replaced by asparagine (N) at position 417. On 22 June, India's Ministry of Health and Family Welfare declared the "Delta plus" variant of COVID-19 a variant of concern, after 22 cases of the variant were reported in India. After the announcement, leading virologists said there was insufficient data to support labelling the variant as a distinct variant of concern, pointing to the small number of patients studied. In the UK in July 2021, AY.4.2 was identified. Alongside those previously mentioned it also gained the nickname 'Delta Plus', on the strength of its extra mutations, Y145H and A222V. These are not unique to it, but distinguish it from the original Delta variant.

On 7 June 2022, the WHO has de-escalated the Delta variant and its subvariants to "previously circulating variants of concern".

### Previously circulating variants of interest (VOI)

| Pango lineage | GISAID clade | Nextstrain clade | Earliest samples | Date of VOI | Date of designation | Country of sampling | Notes |
| --- | --- | --- | --- | --- | --- | --- | --- |
| P.2 | GR/484K.V2 | 20B/S.484K | 2020-04 | 2021-07-06 | 2021-08-17 |  | Zeta variant |
| P.3 | GR/1092K.V1 | 21E | 2021-01 | 2021-07-06 | 2021-08-17 |  | Theta variant |
| B.1.427
B.1.429 | GH/452R.V1 | 21C | 2020-03 | 2021-07-06 | 2021-11-09 |  | Epsilon variant |
| B.1.617.1 | G/452R.V3 | 21B | 2020-10 |  | 2021-09-20 |  | Kappa variant |
| B.1.526 | GH/253G.V1 | 21F | 2020-11 |  | 2021-09-20 |  | Iota variant |
| B.1.525 | G/484K.V3 | 21D | 2020-12 |  | 2021-09-20 |  | Eta variant |
| C.37 | GR/452Q.V1 | 21G | 2020-12 | 2021-06-14 | 2022-03-09 |  | Lambda variant |
| B.1.621 | GH | 21H | 2021-01 | 2021-08-30 | 2022-03-09 |  | Mu variant |

#### Epsilon (lineages B.1.429, B.1.427, CAL.20C)

The Epsilon variant or lineage B.1.429, also known as CAL.20C or CA VUI1, 21C or 20C/S:452R, is defined by five distinct mutations (I4205V and D1183Y in the ORF1ab gene, and S13I, W152C, L452R in the spike protein's S-gene), of which the L452R (previously also detected in other unrelated lineages) was of particular concern. From 17 March to 29 June 2021, the CDC listed B.1.429 and the related B.1.427 as "variants of concern". As of July 2021, Epsilon is no longer considered a variant of interest by the WHO, as it was overtaken by Alpha.

From September 2020 to January 2021, it was 19% to 24% more transmissible than earlier variants in California. Neutralisation against it by antibodies from natural infections and vaccinations was moderately reduced, but it remained detectable in most diagnostic tests.

Epsilon (CAL.20C) was first observed in July 2020 by researchers at the Cedars-Sinai Medical Center, California, in one of 1,230 virus samples collected in Los Angeles County since the start of the COVID-19 epidemic. It was not detected again until September when it reappeared among samples in California, but numbers remained very low until November. In November 2020, the Epsilon variant accounted for 36 per cent of samples collected at Cedars-Sinai Medical Center, and by January 2021, the Epsilon variant accounted for 50 per cent of samples. In a joint press release by University of California, San Francisco, California Department of Public Health, and Santa Clara County Public Health Department, the variant was also detected in multiple counties in Northern California. From November to December 2020, the frequency of the variant in sequenced cases from Northern California rose from 3% to 25%. In a preprint, CAL.20C is described as belonging to clade 20C and contributing approximately 36% of samples, while an emerging variant from the 20G clade accounts for some 24% of the samples in a study focused on Southern California. Note, however, that in the US as a whole, the 20G clade predominates, as of January 2021. Following the increasing numbers of Epsilon in California, the variant has been detected at varying frequencies in most US states. Small numbers have been detected in other countries in North America, and in Europe, Asia and Australia. After an initial increase, its frequency rapidly dropped from February 2021 as it was being outcompeted by the more transmissible Alpha. In April, Epsilon remained relatively frequent in parts of northern California, but it had virtually disappeared from the south of the state and had never been able to establish a foothold elsewhere; only 3.2% of all cases in the United States were Epsilon, whereas more than two-thirds were Alpha.

#### Zeta (lineage P.2)

Under the simplified naming scheme proposed by the World Health Organization, P.2 was labeled "Zeta variant", and was considered a variant of interest (VOI), but not a variant of concern. A second wave was preceded in November 2020 by an increase in the prevalence of the Zeta variant among genetic sequences from São Paulo state, deposited into the GISAID database. As of July 2021, Zeta is no longer considered a variant of interest by the WHO.

#### Eta (lineage B.1.525)

The Eta variant or lineage B.1.525, also called VUI-21FEB-03 (previously VUI-202102/03) by Public Health England (PHE) and formerly known as UK1188, 21D or 20A/S:484K, does not carry the same N501Y mutation found in Alpha, Beta and Gamma, but carries the same E484K-mutation as found in the Gamma, Zeta, and Beta variants, and also carries the same ΔH69/ΔV70 deletion (a deletion of the amino acids histidine and valine in positions 69 and 70) as found in Alpha, N439K variant (B.1.141 and B.1.258) and Y453F variant (Cluster 5). Eta differs from all other variants by having both the E484K-mutation and a new F888L mutation (a substitution of phenylalanine (F) with leucine (L) in the S2 domain of the spike protein). As of 5 March 2021, it had been detected in 23 countries. It has also been reported in Mayotte, the overseas department/region of France. The first cases were detected in December 2020 in the UK and Nigeria, and as of 15 February 2021, it had occurred in the highest frequency among samples in the latter country. As of 24 February 56 cases were found in the UK. Denmark, which sequences all its COVID-19 cases, found 113 cases of this variant from 14 January to 21 February 2021, of which seven were directly related to foreign travel to Nigeria.

As of July 2021, UK experts are studying it to ascertain how much of a risk it could be. It is currently regarded as a "variant under investigation", but pending further study, it may become a "variant of concern". Ravi Gupta, from the University of Cambridge said in a BBC interview that lineage B.1.525 appeared to have "significant mutations" already seen in some of the other newer variants, which means their likely effect is to some extent more predictable.

#### Theta (lineage P.3)

On 18 February 2021, the Department of Health of the Philippines confirmed the detection of two mutations of COVID-19 in Central Visayas after samples from patients were sent to undergo genome sequencing. The mutations were later named as E484K and N501Y, which were detected in 37 out of 50 samples, with both mutations co-occurrent in 29 out of these.

On 13 March, the Department of Health confirmed the mutations constitutes a variant which was designated as lineage P.3. On the same day, it also confirmed the first COVID-19 case caused by the Gamma variant in the country. The Philippines had 98 cases of the Theta variant on 13 March. On 12 March it was announced that Theta had also been detected in Japan. On 17 March, the United Kingdom confirmed its first two cases, where PHE termed it VUI-21MAR-02. On 30 April 2021, Malaysia detected 8 cases of the Theta variant in Sarawak.

As of July 2021, Theta is no longer considered a variant of interest by the WHO.

#### Iota (lineage B.1.526)

Iota variant, also known as lineage B.1.526, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in New York City in November 2020. The variant has appeared with two notable mutations: the E484K spike mutation, which may help the virus evade antibodies, and the S477N mutation, which helps the virus bind more tightly to human cells.

The proportion of USA cases represented by the Iota variant had declined sharply by the end of July 2021 as the Delta variant became dominant.

#### Kappa (lineage B.1.617.1)

Kappa variant is a variant of SARS-CoV-2, the virus that causes COVID-19. It is one of the three sublineages of Pango lineage B.1.617. The SARS-CoV-2 Kappa variant is also known as lineage B.1.617.1 and was first detected in India in December 2020. By the end of March 2021, the Kappa sub-variant accounted for more than half of the sequences being submitted from India. On 1 April 2021, it was designated a Variant Under Investigation (VUI-21APR-01) by Public Health England.

#### Lambda (lineage C.37)

The Lambda variant, also known as lineage C.37, is a variant of SARS-CoV-2, the virus that causes COVID-19. It was first detected in Peru in August 2020. On 14 June 2021, the World Health Organization (WHO) named it Lambda variant and designated it as a variant of interest. On 16 March 2022, the WHO has de-escalated the Lambda variant to "previously circulating variants of concern".

#### Mu (lineage B.1.621)

The Mu variant, also known as lineage B.1.621 or VUI-21JUL-1, is one of the variants of SARS-CoV-2, the virus that causes COVID-19. It was first detected in Colombia in January 2021 and was designated by the WHO as a variant of interest on August 30, 2021. On 16 March 2022, the WHO has de-escalated the Mu variant and its subvariants to "previously circulating variants of concern".

### Formerly monitored variants (WHO)

The variants listed below were once listed under variants under monitoring, but were reclassified due to either no longer circulating at a significant level, not having had a significant impact on the situation, or scientific evidence of the variant not having concerning properties.

|
|  |
As of 26 May 2022
| Pango lineage | GISAID clade | Nextstrain clade | Earliest samples | Date of VUM | Date of designation | Country of sampling |
| --- | --- | --- | --- | --- | --- | --- |
| AV.1 | GR |  | 2021-03 | 2021-05-26 | 2021-07-21 | UK |
| AT.1 | GR |  | 2021-01 | 2021-06-09 | 2021-07-21 | Russia |
| R.1 | GR |  | 2021-01 | 2021-04-07 | 2021-11-09 | Japan |
| B.1.466.2 | GH |  | 2020-11 | 2021-04-28 | 2021-11-09 | Indonesia |
| B.1.1.519 | GR | 20B/S.732A | 2020-11 | 2021-06-02 | 2021-11-09 | Multiple countries |
| C.36.3 | GR |  | 2021-01 | 2021-06-16 | 2021-11-09 | Multiple countries |
| B.1.214.2 | G |  | 2020-11 | 2021-06-30 | 2021-11-09 | Multiple countries |
| B.1.1.523 | GR |  | 2020-05 | 2021-07-14 | 2021-11-09 | Multiple countries |
| B.1.619 | G |  | 2020-05 | 2021-07-14 | 2021-11-09 | Multiple countries |
| B.1.620 | G | 20A/S.126A | 2020-11 | 2021-07-14 | 2021-11-09 | Lithuania |
| B.1.1.318 AZ.5 | GR |  | 2021-01 |  | 2021-06-02 | England |
| C.1.2 | GR |  | 2021-05 |  | 2021-09-01 | South Africa |
| B.1.630 | GH |  | 2021-03 |  | 2021-10-12 | Dominican Republic |
| B.1.640 | GH/490R |  | 2021-09 |  | 2021-11-22 | Republic of Congo |
| XD |  |  | 2022-01 |  | 2022-03-09 | France |

## Omicron

### Lineage B.1.1.529

The Omicron variant, known as lineage B.1.1.529, was declared a variant of concern by the World Health Organization on 26 November 2021.

The variant has a large number of mutations, of which some are concerning. Some evidence shows that this variant has an increased risk of reinfection. Studies are underway to evaluate the exact impact on transmissibility, mortality, and other factors.

Named Omicron by the WHO, it was identified in November 2021 in Botswana and South Africa; one case had travelled to Hong Kong, one confirmed case was identified in Israel in a traveler returning from Malawi, along with two who returned from South Africa and one from Madagascar. Belgium confirmed the first detected case in Europe on 26 November 2021 in an individual who had returned from Egypt on 11 November. Indian SARS-CoV-2 Genomics Consortium (INSACOG) in its January 2022 bulletin noted that Omicron is in community transmission in India where new cases have been rising exponentially.

### BA. sublineages

According to the WHO, BA.1, BA.1.1, and BA.2 were the most common sublineages of Omicron globally as of February 2022. BA.2 contains 28 unique genetic changes, including four in its spike protein, compared to BA.1, which had already acquired 60 mutations since the ancestral Wuhan strain, including 32 in the spike protein. BA.2 is more transmissible than BA.1. It was causing most cases in England by mid-March 2022, and by the end of March, BA.2 became dominant in the US. As of May 2022, the sublineages BA.1 to BA.5 including all their descendants are classified as variants of concern by the WHO, the CDC, and the ECDC (with the latter excluding BA.3).

### XBB sublineages

During 2022, a number of further new strains emerged in different localities, including XBB.1.5, which evolved from the XBB strain of Omicron. The first case involving XBB in England was detected from a specimen sample taken on 10 September 2022 and further cases have since been identified in most English regions. By the end of the year, XBB.1.5 accounted for 40.5% of new cases across the US, and was the dominant strain; variant of concern BQ.1 was running at 18.3% and BQ.1.1 represented 26.9% of new cases, while the BA.5 strain was in decline, at 3.7%. At this stage, it was uncommon in many other countries, for example in the UK it was represented about 7% of new cases, according to UKHSA sequencing data.

On 22 December 2022, the European Centre for Disease Control wrote in a summary that XBB strains accounted for circa 6.5% of new cases in five EU countries with sufficient volume of sequencing or genotyping to provide estimates.

EG.5, a subvariant of XBB.1.9.2, (nicknamed "Eris" by some media) emerged in February 2023. On 6 August 2023, the UK Health Security Agency reported the EG.5 strain was responsible for one in seven new cases in the UK during the third week of July.

### Lineage BA.2.86

During 2023, SARS-CoV-2 continued to circulate in the global population and to evolve, with a number of new subvariants. Testing, sequencing and reporting rates reduced.

BA.2.86 was first detected in a sample from 24 July 2023, and was designated as a variant under monitoring by the World Health Organization on 17 August 2023.

JN.1 (sometimes referred to as "Pirola"), a subvariant of BA.2.86, emerged during August 2023 in Luxembourg. By December 2023, it had been detected in 12 countries, including the UK and US. On 19 December, JN.1 was declared by the WHO to be a variant of interest independently of its parent strain BA.2.86, but overall risk for public health was determined as low. With JN.1 accounting for some 60% of cases in Singapore, in December 2023, Singapore and Indonesia recommended wearing masks at airports. The CDC estimated that the variant accounted for 44% of cases in the US on 22 December 2023 and 62% of cases on 5 January 2024.

As of 9 February 2024, JN.1 was estimated by the WHO to be the most prevalent variant of SARS-CoV-2 (70–90% prevalence in four out of six global regions; insufficient data in the East Mediterranean and African regions). The general level of population immunity and immunity from XBB.1.5 booster versions of the COVID-19 vaccine was expected to provide some protection (cross-reactivity) to JN.1.

### Sublineages by year

#### 2024

Late in April 2024, CDC data showed KP.2 to be the most common U.S. variant, with a quarter of all cases, just ahead of JN.1. KP1.1 represented 7 percent of U.S. cases. These two are sometimes referred to as the 'FLiRT' variants because they are characterized by a phenylalanine (F) to leucine (L) mutation and an arginine (R) to threonine (T) mutation in the virus's spike protein. By July 2024, a descendant of KP.2 with an extra amino acid change in the spike protein, Q493E, was given the names KP.3 and, informally, 'FLuQE,' and became a major variant in New South Wales during the Australian winter. Initial research suggested that the Q493E change could help KP.3 be more effective at binding to human cells than KP.2.

As of September 2024, XEC, first found in Germany, is expected to be the next major variant. XEC is a recombination of two subvariants: KS.1.1 and KP.3.3. Only a few cases have been detected in the United States, but it is reported to have a slight advantage over other variants in terms of transmissibility.

## Omicron variants under monitoring (WHO, 2022/2023)

On 25 May 2022, the World Health Organization introduced a new category for potentially concerning sublineages of widespread variants of concern, initially called VOC lineages under monitoring (VOC-LUMs). This decision was made to reflect that in February 2022, over 98% of all GISAID sequenced samples belonged to the Omicron family, within which much of the variants' evolution took place. By 9 February 2023, the category had been renamed as "Omicron variants under monitoring."

|
|  |
As of 9 February 2023
| Pango lineage | GISAID clade | Nextstrain clade | Relation to circulating VOCs | First documented | Notable features |
| --- | --- | --- | --- | --- | --- |
| BF.7 | GRA | 22B | BA.5 sublineage | 2022-01-24 | BA.5 + S:R346T |
| BQ.1 | GRA | 22E | BA.5 sublineage | 2022-02-07 | BQ.1 and BQ.1.1: BA.5 + S:R346T, S:K444T, S:N460K |
| BA.2.75 | GRA | 22D | BA.2 sublineage | 2021-12-31 | BA.2.75: BA.2 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:D339H, S:G446S, S:N460K, S:Q493R reversion |
| CH.1.1 | GRA | 22D | BA.2 sublineage | 2022-07-20 | BA.2.75 + S:L452R, S:F486S |
| XBB | GRA | 22F | Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1, with a breakpoint in S1 | 2022-08-13 | BA.2+ S:V83A, S:Y144-, S:H146Q, S:Q183E, S:V213E, S:G252V, S:G339H, S:R346T, S:L368I, S:V445P, S:G446S, S:N460K, S:F486S, S:F490S |
| XBB.1.5 | GRA | 23A | Recombinant of BA.2.10.1 and BA.2.75 sublineages, i.e. BJ1 and BM.1.1.1, with a breakpoint in S1 | 2022-01-05 | XBB + S:F486P |
| XBF | GRA |  | Recombinant of BA.5.2.3 and CJ.1 (BA.2.75.3 sublineage) | 2022-07-20 | BA.5 + S:K147E, S:W152R, S:F157L, S:I210V, S:G257S, S:G339H, S:R346T, S:G446S, S:N460K, S:F486P, S:F490S |
| JN.1 | GRA | 24A | BA.2.86 sublineage; genetic features include S:L455S | 2023-08-25 | As of 28 June 2024, classified as a VOI; "Omicron VOC" category no longer declared |

## Other notable variants

Lineage B.1.1.207 was first sequenced in August 2020 in Nigeria; the implications for transmission and virulence are unclear but it has been listed as an emerging variant by the US Centers for Disease Control. Sequenced by the African Centre of Excellence for Genomics of Infectious Diseases in Nigeria, this variant has a P681H mutation, shared in common with the Alpha variant. It shares no other mutations with the Alpha variant and as of late December 2020 this variant accounts for around 1% of viral genomes sequenced in Nigeria, though this may rise. As of May 2021, lineage B.1.1.207 has been detected in 10 countries.

Lineage B.1.1.317, while not considered a variant of concern, is noteworthy in that Queensland Health forced 2 people undertaking hotel quarantine in Brisbane, Australia to undergo an additional 5 days' quarantine on top of the mandatory 14 days after it was confirmed they were infected with this variant.

Lineage B.1.616, being identified in Brittany, Western France in early January 2021 and designated by WHO as "Variant under investigation" in March 2021, was reported to be difficult to detect from nasopharyngeal swab sampling method of coronavirus detection, and detection of the virus needs to rely on samples from lower respiratory tract.

Lineage B.1.618 was first isolated in October 2020. It has the E484K mutation in common with several other variants, and showed significant spread in April 2021 in West Bengal, India. As of 23 April 2021, the PANGOLIN database showed 135 sequences detected in India, with single-figure numbers in each of eight other countries worldwide.

In July 2021, scientists reported in a preprint which was published in a journal in February 2022, the detection of anomalous unnamed unknown-host SARS-CoV-2 lineages via wastewater surveillance in New York City. They hypothesized that "these lineages are derived from unsampled human COVID-19 infections or that they indicate the presence of a non-human animal reservoir".

Lineage B.1.640.2 (also known as the IHU variant) was detected in October 2021 by researchers at the Institut Hospitalo-Universitaire (IHU) in Marseille. They found the variant in a traveler who returned to France from Cameroon and reportedly infected 12 people. The B.1.640 lineage, which includes B.1.640.2, was designated a variant under monitoring (VUM) by the World Health Organization (WHO) on 22 November 2021. However, the WHO has reported that lineage B.1.640.2 has spread much slower than the Omicron variant, and so is of relatively little concern. According to a preprint study, lineage B.1.640.2 has two already known spike protein mutations – E484K and N501Y – among a total of 46 nucleotide substitutions and 37 deletions.

In March 2022, researchers reported SARS-CoV-2 variant recombinant viruses that contain elements of Delta and Omicron – Deltacron (also called "Deltamicron"). Recombination occurs when a virus combines parts from a related virus with its genetic sequence as it assembles copies of itself. It is unclear whether Deltacron – which is not to be confused with "Deltacron" reported in January albeit the first detection was also in January – will be able to compete with Omicron and whether that would be detrimental to health.

In July 2023, Professor Lawrence Young, a virologist at Warwick University announced a super mutated Delta variant from a swab of an Indonesian case with 113 unique mutations, with 37 affecting the spike protein.

## Recombinant variants

In 2022, the British government reported a number of recombinant variants of SARS-CoV-2. These recombinant lineages have been given the Pango lineage identifiers XD, XE, and XF.

XE is a recombinant lineage of Pango lineages BA.1 and BA.2. As of March 2022 XE was believed to have a growth rate 9.8% greater than BA.2.

## Incubation theory for multiple mutated variants

Researchers have suggested that multiple mutations can arise in the course of the persistent infection of an immunocompromised patient, particularly when the virus develops escape mutations under the selection pressure of antibody or convalescent plasma treatment, with the same deletions in surface antigens repeatedly recurring in different patients.

## Notable missense mutations

There have been a number of missense mutations observed of SARS-CoV-2.

### del 69-70

The name of the mutation, del 69-70, or 69-70 del, or other similar notations, refers to the deletion of amino acid at position 69 to 70. The mutation is found in the Alpha variant, and could lead to "spike gene target failure" and result in false negative result in PCR virus test.

### RSYLTPGD246-253N

Otherwise referred to as del 246-252, or other various similar expression, refer to the deletion of amino acid from the position of 246 to 252, in the N-terminal domain of spike protein, accompanied with a replacement of the aspartic acid (D) at the position 253 for asparagine (N).

The 7 amino acid deletion mutation is currently described as unique in the Lambda variant, and have been attributed to as one of the cause of the strain's increased capability to escape from neutralizing antibodies according to preprint paper.

### N440K

The name of the mutation, N440K, refers to an exchange whereby the asparagine (N) is replaced by lysine (K) at position 440.

This mutation has been observed in cell cultures to be 10 times more infective compared to the previously widespread A2a strain (A97V substitution in RdRP sequence) and 1000 times more in the lesser widespread A3i strain (D614G substitution in Spike and a and P323L substitution in RdRP). It was involved in rapid surges of COVID-19 cases in India in May 2021. India has the largest proportion of N440K mutated variants followed by the US and Germany.

### G446V

The name of the mutation, G446V, refers to an exchange whereby the glycine (G) is replaced by valine (V) at position 446.

The mutation, identified in Japan among inbound travelers starting from May, and among 33 samples from individuals related to 2020 Tokyo Olympic Games and 2020 Tokyo Paralympic Games, are said to be possible to impact affinity of multiple monoclonal antibody, although its clinical impact against the use of antibody medicine is still yet to be known.

### L452R

The name of the mutation, L452R, refers to an exchange whereby the leucine (L) is replaced by arginine (R) at position 452.

L452R is found in both the Delta and Kappa variants which first circulated in India, but have since spread around the world. L452R is a relevant mutation in this strain that enhances ACE2 receptor binding ability and can reduce vaccine-stimulated antibodies from attaching to this altered spike protein.

L452R, some studies show, could even make the coronavirus resistant to T cells, that are necessary to target and destroy virus-infected cells. They are different from antibodies that are useful in blocking coronavirus particles and preventing it from proliferating.

### Y453F

The name of the mutation, Y453F, refers to an exchange whereby the tyrosine (Y) is replaced by phenylalanine (F) at position 453. The mutation have been found potentially linked to the spread of SARS-CoV-2 among minks in the Netherlands in 2020.

### S477G/N

A highly flexible region in the receptor binding domain (RBD) of SARS-CoV-2, starting from residue 475 and continuing up to residue 485, was identified using bioinformatics and statistical methods in several studies. The University of Graz and the Biotech Company Innophore have shown in a recent publication that structurally, the position S477 shows the highest flexibility among them.

At the same time, S477 is hitherto the most frequently exchanged amino acid residue in the RBDs of SARS-CoV-2 mutants. By using molecular dynamics simulations of RBD during the binding process to hACE2, it has been shown that both S477G and S477N strengthen the binding of the SARS-COV-2 spike with the hACE2 receptor. The vaccine developer BioNTech referenced this amino acid exchange as relevant regarding future vaccine design in a preprint published in February 2021.

### E484Q

The name of the mutation, E484Q, refers to an exchange whereby the glutamic acid (E) is replaced by glutamine (Q) at position 484.

The Kappa variant circulating in India has E484Q. These variants were initially (but misleadingly) referred to as a "double mutant". E484Q may enhance ACE2 receptor binding ability, and may reduce vaccine-stimulated antibodies' ability to attach to this altered spike protein.

### E484K

The name of the mutation, E484K, refers to an exchange whereby the glutamic acid (E) is replaced by lysine (K) at position 484. It is nicknamed "Eeek".

E484K has been reported to be an escape mutation (i.e., a mutation that improves a virus's ability to evade the host's immune system) from at least one form of monoclonal antibody against SARS-CoV-2, indicating there may be a "possible change in antigenicity". The Gamma variant (lineage P.1), the Zeta variant (lineage P.2, also known as lineage B.1.1.28.2) and the Beta variant (501.V2) exhibit this mutation. A limited number of lineage B.1.1.7 genomes with E484K mutation have also been detected. Monoclonal and serum-derived antibodies are reported to be from 10 to 60 times less effective in neutralising virus bearing the E484K mutation. On 2 February 2021, medical scientists in the United Kingdom reported the detection of E484K in 11 samples (out of 214,000 samples), a mutation that may compromise current vaccine effectiveness.

### F490S

F490S denotes a change from phenylalanine (F) to serine (S) in amino-acid position 490.

It is one of the mutation found in Lambda, and have been associated with reduced susceptibility to antibody generated by those who were infected with other strains, meaning antibody treatment against people infected with strains carrying such mutation would be less effective.

### N501Y

N501Y denotes a change from asparagine (N) to tyrosine (Y) in amino-acid position 501. N501Y has been nicknamed "Nelly".

This change is believed by PHE to increase binding affinity because of its position inside the spike glycoprotein's receptor-binding domain, which binds ACE2 in human cells; data also support the hypothesis of increased binding affinity from this change. Molecular interaction modelling and the free energy of binding calculations has demonstrated that the mutation N501Y has the highest binding affinity in variants of concern RBD to hACE2. Variants with N501Y include Gamma, Alpha (VOC 20DEC-01), Beta, and COH.20G/501Y (identified in Columbus, Ohio). This last became the dominant form of the virus in Columbus in late December 2020 and January and appears to have evolved independently of other variants.

### N501S

N501S denotes a change from asparagine (N) to serine (S) in amino-acid position 501.

As of September 2021, there are 8 cases of patients around the world infected with Delta variant which feature this N501S mutation. As it is considered a mutation similar to N501Y, it is suspected to have similar characteristics as N501Y mutation, which is believed to increase the infectivity of the virus, however the exact effect is unknown yet.

### D614G

D614G is a missense mutation that affects the spike protein of SARS-CoV-2. From early appearances in Eastern China early in 2020, the frequency of this mutation in the global viral population increased early on during the pandemic. G (glycine) quickly replaced D (aspartic acid) at position 614 in Europe, though more slowly in China and the rest of East Asia, supporting the hypothesis that G increased the transmission rate, which is consistent with higher viral titres and infectivity in vitro. Researchers with the PANGOLIN tool nicknamed this mutation "Doug".

In July 2020, it was reported that the more infectious D614G SARS-CoV-2 variant had become the dominant form in the pandemic. PHE confirmed that the D614G mutation had a "moderate effect on transmissibility" and was being tracked internationally.

The global prevalence of D614G correlates with the prevalence of loss of smell (anosmia) as a symptom of COVID-19, possibly mediated by higher binding of the RBD to the ACE2 receptor or higher protein stability and hence higher infectivity of the olfactory epithelium.

Variants containing the D614G mutation are found in the G clade by GISAID and the B.1 clade by the PANGOLIN tool.

### Q677P/H

The name of the mutation, Q677P/H, refers to an exchange whereby the glutamine (Q) is replaced by proline (P) or histidine (H) at position 677. There are several sub-lineages containing the Q677P mutation; six of these, which also contain various different combinations of other mutations, are referred to by names of birds. One of the earlier ones noticed for example is known as "Pelican," while the most common of these as of early 2021 was provisionally named "Robin 1."

The mutation has been reported in multiple lineages circulating inside the United States as of late 2020 and also some lineages outside the country. 'Pelican' was first detected in Oregon, and as of early 2021 'Robin 1' was found often in the Midwestern United States, while another Q667H sub-lineage, 'Robin 2', was found mostly in the southeastern United States. The frequency of such mutation being recorded has increased from late 2020 to early 2021.

### P681H

The name of the mutation, P681H, refers to an exchange whereby the proline (P) is replaced by histidine (H) at position 681.

In January 2021, scientists reported in a preprint that the mutation P681H, a characteristic feature of the Alpha variant and lineage B.1.1.207 (identified in Nigeria), is showing a significant exponential increase in worldwide frequency, thus following a trend to be expected in the lower limb of the logistics curve. This may be compared with the trend of the now globally prevalent D614G.

### P681R

The name of the mutation, P681R, refers to an exchange whereby the proline (P) is replaced by arginine (R) at position 681.

Indian SARS-CoV-2 Genomics Consortium (INSACOG) found that other than the two mutations E484Q and L452R, there is also a third significant mutation, P681R in lineage B.1.617. All three concerning mutations are on the spike protein, the operative part of the coronavirus that binds to receptor cells of the body.

### A701V

According to initial media reports, the Malaysian Ministry of Health announced on 23 December 2020 that it had discovered a mutation in the SARS-CoV-2 genome which they designated as A701B(sic), among 60 samples collected from the Benteng Lahad Datu cluster in Sabah. The mutation was characterised as being similar to the one found recently at that time in South Africa, Australia, and the Netherlands, although it was uncertain if this mutation was more infectious or aggressive than before. The provincial government of Sulu in neighbouring Philippines temporarily suspended travel to Sabah in response to the discovery of 'A701B' due to uncertainty over the nature of the mutation.

On 25 December 2020, the Malaysian Ministry of Health described a mutation A701V as circulating and present in 85% of cases (D614G was present in 100% of cases) in Malaysia. These reports also referred to samples collected from the Benteng Lahad Datu cluster. The text of the announcement was mirrored verbatim on the Facebook page of Noor Hisham Abdullah, Malay Director-General of Health, who was quoted in some of the news articles.

The A701V mutation has the amino acid alanine (A) substituted by valine (V) at position 701 in the spike protein. Globally, South Africa, Australia, Netherlands and England also reported A701V at about the same time as Malaysia. In GISAID, the prevalence of this mutation is found to be about 0.18%. of cases.

On 14 April 2021, the Malaysian Ministry of Health reported that the third wave, which had started in Sabah, has involved the introduction of variants with D614G and A701V mutations.

## Data and methods

Modern DNA sequencing, where available, may permit rapid detection (sometimes known as 'real-time detection') of genetic variants that appear in pathogens during disease outbreaks. Through use of phylogenetic tree visualisation software, records of genome sequences can be clustered into groups of identical genomes all containing the same set of mutations. Each group represents a 'variant', 'clade', or 'lineage', and comparison of the sequences allows the evolutionary path of a virus to be deduced. For SARS-CoV-2, until March 2021, over 330,000 viral genomic sequences had been generated by molecular epidemiology studies across the world.

### New variant detection and assessment

On 26 January 2021, the British government said it would share its genomic sequencing capabilities with other countries in order to increase the genomic sequencing rate and trace new variants, and announced a "New Variant Assessment Platform". As of January 2021, more than half of all genomic sequencing of COVID-19 was carried out in the UK.

Wastewater surveillance was demonstrated to be one technique to detect SARS-CoV-2 variants and to track their rise for studying related ongoing infection dynamics.

### Testing

Whether one or more mutations visible in RT-PCR tests can be used reliably to identify a variant depends on the prevalence of other variants currently circulating in the same population.

Mutations used to identify variants of concern in commercial test assays
| Mutation | Alpha | Beta | Gamma | Delta | Omicron |
| --- | --- | --- | --- | --- | --- |
| Δ69–70 |  |  |  |  |  |
| ins214EPE |  |  |  |  |  |
| S371L/S373P |  |  |  |  |  |
| N501Y |  |  |  |  |  |
| E484K |  |  |  |  |  |
| E484A |  |  |  |  |  |
| L452R |  |  |  |  |  |
| nsp6:Δ106–108 |  |  |  |  |  |

## Cross-species transmission

There is a risk that COVID-19 could transfer from humans to other animal populations and could combine with other animal viruses to create yet more variants that are dangerous to humans. Reverse zoonosis spillovers may cause reservoirs for mutating variants that spill back to humans – another possible source for variants of concern, in addition to immunocompromised people.

### Cluster 5

In early November 2020, Cluster 5, also referred to as ΔFVI-spike by the Danish State Serum Institute (SSI), was discovered in Northern Jutland, Denmark. It is believed to have been spread from minks to humans via mink farms. On 4 November 2020, it was announced that the mink population in Denmark would be culled to prevent the possible spread of this mutation and reduce the risk of new mutations happening. A lockdown and travel restrictions were introduced in seven municipalities of Northern Jutland to prevent the mutation from spreading, which could compromise national or international responses to the COVID-19 pandemic. By 5 November 2020, some 214 mink-related human cases had been detected.

The WHO stated that cluster 5 had a "moderately decreased sensitivity to neutralising antibodies". SSI warned that the mutation could reduce the effect of COVID-19 vaccines under development, although it was unlikely to render them useless. Following the lockdown and mass-testing, SSI announced on 19 November 2020 that cluster 5 in all probability had become extinct. As of 1 February 2021, authors to a peer-reviewed paper, all of whom were from the SSI, assessed that cluster 5 was not in circulation in the human population.

## Vaccines

During the COVID-19 pandemic, a variety of vaccines was developed. The vaccines were rolled out for administering to a broad range of recipients, typically beginning with the most vulnerable demographic groups.

### Differential vaccine effectiveness

The interplay between the SARS-CoV-2 virus and its human hosts was initially natural but then started being altered by the rising availability of vaccines seen in 2021. The potential emergence of a SARS-CoV-2 variant that is moderately or fully resistant to the antibody response elicited by the COVID-19 vaccines may necessitate modification of the vaccines. The emergence of vaccine-resistant variants is more likely in a highly vaccinated population with uncontrolled transmission.

As of February 2021, the US Food and Drug Administration believed that all FDA authorized vaccines remained effective in protecting against circulating strains of SARS-CoV-2.

#### Immune evasion by variants

In contrast to other investigated prior variants, the SARS-CoV-2 Omicron variant and its BA.4/5 subvariants have evaded immunity induced by vaccines, which may lead to breakthrough infections despite recent vaccination. Nevertheless, vaccines are thought to provide protection against severe illness, hospitalizations, and deaths due to Omicron.

#### Vaccine adjustments

In June 2022, Pfizer and Moderna developed bivalent vaccines to protect against the SARS-CoV-2 wild-type and the Omicron variant. The bivalent vaccines are well-tolerated and offer immunity to Omicron superior to previous mRNA vaccines. In September 2022, the United States Food and Drug Administration (FDA) authorized the bivalent vaccines.

In June 2023, the FDA advised manufacturers that the 2023–2024 formulation of the COVID19 vaccines for use in the US be updated to be a monovalent COVID19 vaccine using the XBB.1.5 lineage of the Omicron variant. In June 2024, the FDA advised manufacturers that the 2024–2025 formulation of the COVID19 vaccines for use in the US be updated to be a monovalent COVID19 vaccine using the JN.1 lineage.     1. In another source, GISAID name a set of 7 clades without the O clade but including a GV clade.
2. According to the WHO, "Lineages or clades can be defined based on viruses that share a phylogenetically determined common ancestor".
3. As of January 2021, at least one of the following criteria must be met in order to count as a clade in the Nextstrain system (quote from source):
> 1. A clade reaches \>20% global frequency for 2 or more months
>     2. A clade reaches \>30% regional frequency for 2 or more months
>     3. A VOC ('variant of concern') is recognized (applies currently \[6 January 2021\] to 501Y.V1 and 501Y.V2)
4. Based on various trackers and periodic reports.
5. Produces S gene target failure (SGTF) in TaqPath.
6. Detectable by the TIB MolBiol assay using the melting curve method.
7.
1. Shahhosseini N, Babuadze GG, Wong G, Kobinger GP (April 2021). "Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern". *Microorganisms*. **9** (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854. S2CID 233460887.
2. "Coronavirus variants and mutations: The science explained". *BBC News*. 6 January 2021. Archived from the original on 22 February 2021. Retrieved 2 February 2021.
3. Kupferschmidt K (15 January 2021). "New coronavirus variants could cause more reinfections, require updated vaccines". *Science*. doi:10.1126/science.abg6028. S2CID 234141081. Archived from the original on 22 February 2021. Retrieved 2 February 2021.
4. "WHO Coronavirus Network (CoViNet)". Retrieved 1 September 2024.
5. "Origins of Coronaviruses". *NIH.gov*. National Institutes of Health in the United States. 16 March 2022. Archived from the original on 21 January 2023. Retrieved 3 February 2023. To date, the origin of SARS-CoV-2 which caused the COVID-19 pandemic has not been identified.
6. Shahhosseini N, Wong G, Kobinger GP, Chinikar S (June 2021). "SARS-CoV-2 spillover transmission due to recombination event". *Gene Reports*. **23**: 101045. doi:10.1016/j.genrep.2021.101045. PMC 7884226. PMID 33615041.
7. "The rise and fall of the lab leak hypothesis for the origin of SARS-CoV-2 | Science-Based Medicine". *sciencebasedmedicine.org*. 1 August 2022. Retrieved 4 November 2022.
8. Tang X, Wu C, Li X, Song Y (3 March 2020). "On the origin and continuing evolution of SARS-CoV-2". *National Science Review*. **7** (6): 1012–1023. doi:10.1093/nsr/nwaa036. PMC 7107875. PMID 34676127. (Erratum: doi:10.1093/nsr/nwaa036,  *Retraction Watch*)
9. Forster P, Forster L, Renfrew C, Forster M (8 April 2020). "Phylogenetic network analysis of SARS-CoV-2 genomes". *Proceedings of the National Academy of Sciences*. **117** (17): 9241–9243. Bibcode:2020PNAS..117.9241F. doi:10.1073/pnas.2004999117. ISSN 0027-8424. PMC 7196762. PMID 32269081.
10. Rambaut A, Holmes EC, OToole A, Hill V, McCrone JT, Ruis C, et al. (15 July 2020). "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology". *Nature Microbiology*. **5** (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681.
11. Tregoning JS, Flight KE, Higham SL, Wang Z, Pierce BF (9 August 2021). "Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape". *Nature Reviews Immunology*. **21** (10): 626–636. doi:10.1038/s41577-021-00592-1. PMC 8351583. PMID 34373623.
12. Piplani S, Singh PK, Winkler DA, Petrovsky N (December 2021). "In silico comparison of SARS-CoV-2 spike protein-ACE2 binding affinities across species and implications for virus origin". *Scientific Reports*. **11** (1): 13063. Bibcode:2021NatSR..1113063P. doi:10.1038/s41598-021-92388-5. PMC 8225877. PMID 34168168.
13. Gallagher J (12 June 2021). "Covid: Is there a limit to how much worse variants can get?". *BBC*. Archived from the original on 15 June 2021. Retrieved 12 June 2021.
14. Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, et al. (17 September 2021). "The biological and clinical significance of emerging SARS-CoV-2 variants". *Nature Reviews Genetics*. **22** (12): 757–773. doi:10.1038/s41576-021-00408-x. PMC 8447121. PMID 34535792.
15. Hendy M, Kaufman S, Ponga M (December 2021). "Molecular strategies for antibody binding and escape of SARS-CoV-2 and its mutations". *Scientific Reports*. **11** (1): 21735. Bibcode:2021NatSR..1121735H. doi:10.1038/s41598-021-01081-0. PMC 8571385. PMID 34741079.
16. Shahhosseini N, Babuadze G(, Wong G, Kobinger GP (May 2021). "Mutation Signatures and In Silico Docking of Novel SARS-CoV-2 Variants of Concern". *Microorganisms*. **9** (5): 926. doi:10.3390/microorganisms9050926. PMC 8146828. PMID 33925854.
17. "Tracking SARS-CoV-2 variants". *www.who.int*. Retrieved 28 November 2021.
18. "Variants: distribution of cases data". *GOV.UK*. 28 January 2021. At "Differences between a Variant of Concern and Variant Under Investigation". Retrieved 19 February 2021. SARS-CoV-2 variants, if considered to have concerning epidemiological, immunological, or pathogenic properties, are raised for formal investigation. At this point they are designated Variant Under Investigation (VUI) with a year, month, and number. Following a risk assessment with the relevant expert committee, they may be designated Variant of Concern (VOC)
19. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. (November 2020). "A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology". *Nature Microbiology*. **5** (11): 1403–1407. doi:10.1038/s41564-020-0770-5. PMC 7610519. PMID 32669681. S2CID 220544096. Cited in Alm et al.
20. Bedford T, Hodcroft B, Neher RA (6 January 2021). "Updated Nextstrain SARS-CoV-2 clade naming strategy". *nextstrain.org*. Archived from the original on 18 January 2021. Retrieved 19 January 2021.
21. "clade tree (from 'Clade and lineage nomenclature')". *GISAID*. 4 July 2020. Archived from the original on 9 January 2021. Retrieved 7 January 2021.
22. "Historical working definitions and primary actions for SARS-CoV-2 variants" (PDF). *World Health Organization*. Retrieved 9 September 2024.
23. "Updated working definitions and primary actions for SARSCoV2 variants". *www.who.int*. Retrieved 9 September 2024.
24. "Tracking SARS-CoV-2 variants". *who.int*. World Health Organization. Archived from the original on 18 June 2021. Retrieved 22 June 2021. Updated frequently.
25. "SARS-CoV-2 Variant Classifications and Definitions". *CDC.gov*. Centers for Disease Control and Prevention. 11 February 2020. Archived from the original on 29 June 2021. Retrieved 18 June 2021. Updated frequently.
26. "Statement on the update of WHO's working definitions and tracking system for SARS-CoV-2 variants of concern and variants of interest". *www.who.int*. Retrieved 29 December 2023.
27. "Updated working definitions and primary actions for SARSCoV2 variants". *www.who.int*. Retrieved 29 December 2023.
28. "Emerging SARS-CoV-2 Variants". *CDC.gov* (Science brief). Centers for Disease Control and Prevention. 28 January 2021. Archived from the original on 15 May 2021. Retrieved 4 January 2021.  This article incorporates text from this source, which is in the public domain.
29. IDSA Contributor "COVID "Mega-variant" and eight criteria for a template to assess all variants". *Science Speaks: Global ID News*. 2 February 2021. Archived from the original on 21 April 2021. Retrieved 20 February 2021.
30. "Variants: distribution of cases data". *Public Health England*. Government Digital Service. Archived from the original on 7 June 2021. Retrieved 16 February 2021. Updated frequently. Data up to 19 May 2021 included in the 2 July 2021 update.
31. Griffiths E, Tanner J, Knox N, Hsiao W, Van Domselaar G (15 January 2021). CanCOGeN Interim Recommendations for Naming, Identifying, and Reporting SARS-CoV-2 Variants of Concern (PDF). *CanCOGeN (nccid.ca)* (Report). 1.0. Archived (PDF) from the original on 17 April 2021.
32. This table is an adaptation and expansion of Alm et al., figure 1.
33. Alm E, Broberg EK, Connor T, Hodcroft EB, Komissarov AB, Maurer-Stroh S, et al. (The WHO European Region sequencing laboratories and GISAID EpiCoV group) (August 2020). "Geographical and temporal distribution of SARS-CoV-2 clades in the WHO European Region, January to June 2020". *Euro Surveillance*. **25** (32). doi:10.2807/1560-7917.ES.2020.25.32.2001410. PMC 7427299. PMID 32794443.
34. "Nextclade" (What are the clades?). *nextstrain.org*. Archived from the original on 19 January 2021. Retrieved 19 January 2021.
35. Zhukova A, Blassel L, Lemoine F, Morel M, Voznica J, Gascuel O (November 2020). "Origin, evolution and global spread of SARS-CoV-2". *Comptes Rendus Biologies*. **344**: 57–75. doi:10.5802/crbiol.29. PMID 33274614.
36. "SARS-CoV-2 Variant Classifications and Definitions". *CDC.gov*. Centers for Disease Control and Prevention. 29 June 2021. Archived from the original on 16 June 2021. Retrieved 19 February 2021. Frequently updated.
37. "Genomic epidemiology of novel coronavirus – Global subsampling (Filtered to B.1.617)". *nextstrain.org*. Archived from the original on 13 July 2021. Retrieved 5 May 2021.
38. Zhang W, Davis B, Chen SS, Martinez JS, Plummer JT, Vail E (2021). "Emergence of a Novel SARS-CoV-2 Variant in Southern California". *JAMA*. **325** (13): 1324–1326. doi:10.1001/jama.2021.1612. ISSN 0098-7484. PMC 7879386. PMID 33571356. Retrieved 2 October 2021.
39. "What are the clades?". *clades.nextstrain.org*. Retrieved 29 November 2021.
40. "PANGO lineages-Lineage B.1.1.28". *cov-lineages.org*. Archived from the original on 24 February 2021. Retrieved 4 February 2021.
41. "Variant: 20J/501Y.V3". *covariants.org*. 1 April 2021. Archived from the original on 23 March 2021. Retrieved 6 April 2021.
42. "Don't call it the 'British variant.' Use the correct name: B.1.1.7". *STAT*. 9 February 2021. Archived from the original on 4 June 2021. Retrieved 12 February 2021.
43. Flanagan R (2 February 2021). "Why the WHO won't call it the 'U.K. variant', and you shouldn't either". *CTV News*. Archived from the original on 1 May 2021. Retrieved 12 February 2021.
44. For a list of sources using names referring to the country in which the variants were first identified, see, for example, Talk:South African COVID variant and Talk:U.K. Coronavirus variant.
45. "Today, @WHO announces new, easy-to-say labels for #SARSCoV2 Variants of Concern (VOCs) & Interest (VOIs)". Archived from the original on 7 July 2021. Retrieved 7 July 2021.
46. Branswell H (31 May 2021). "The name game for coronavirus variants just got a little easier". *Stat News*. Archived from the original on 17 June 2021. Retrieved 28 June 2021.
47. World Health Organization (15 January 2021). "Statement on the sixth meeting of the International Health Regulations (2005) Emergency Committee regarding the coronavirus disease (COVID-19) pandemic". Archived from the original on 7 February 2021. Retrieved 18 January 2021.
48. "Covid: WHO renames UK and other variants with Greek letters". *BBC News*. 31 May 2021. Archived from the original on 31 May 2021. Retrieved 7 July 2021.
49. "WHO skipped two Greek alphabet letters in naming coronavirus variant". *The Associated Press*. 27 November 2021.
50. "New COVID variants could be named after constellations once Greek alphabet is used up". Sky News. 8 August 2021. Retrieved 30 November 2021.
51. Koyama T, Platt D, Parida L (July 2020). "Variant analysis of SARS-CoV-2 genomes". *Bulletin of the World Health Organization*. **98** (7): 495–504. doi:10.2471/BLT.20.253591. PMC 7375210. PMID 32742035. We detected in total 65776 variants with 5775 distinct variants.
52. WHO Headquarters (8 January 2021). "3.6 Considerations for virus naming and nomenclature". *SARS-CoV-2 genomic sequencing for public health goals: Interim guidance, 8 January 2021*. World Health Organization. p. 6. Archived from the original on 23 January 2021. Retrieved 2 February 2021.
53. "Global phylogeny, updated by Nextstrain". GISAID. 18 January 2021. Archived from the original on 20 January 2021. Retrieved 19 January 2021.
54. Hadfield J, Megill C, Bell SM, Huddleston J, Potter B, Callender C, et al. (December 2018). Kelso J (ed.). "Nextstrain: real-time tracking of pathogen evolution". *Bioinformatics*. **34** (23): 4121–4123. doi:10.1093/bioinformatics/bty407. PMC 6247931. PMID 29790939.
55. "Nextstrain COVID-19". *Nextstrain*. Archived from the original on 21 January 2021. Retrieved 1 June 2021.
56. "cov-lineages/pangolin: Software package for assigning SARS-CoV-2 genome sequences to global lineages". Github. Archived from the original on 15 February 2021. Retrieved 2 January 2021.
57. "Lineage descriptions". *cov-lineages.org*. Pango team. Archived from the original on 4 June 2021. Retrieved 24 December 2020.
58. Rambaut A, Holmes EC, O'Toole Á, Hill V, McCrone JT, Ruis C, et al. (March 2021). "Addendum: A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology". *Nature Microbiology*. **6** (3): 415. doi:10.1038/s41564-021-00872-5. PMC 7845574. PMID 33514928.
59. Kumar S, Tao Q, Weaver S, Sanderford M, Caraballo-Ortiz MA, Sharma S, et al. (May 2021). "An evolutionary portrait of the progenitor SARS-CoV-2 and its dominant offshoots in COVID-19 pandemic". *Molecular Biology and Evolution*. **38** (8): 3046–3059. doi:10.1093/molbev/msab118. PMC 8135569. PMID 33942847.
60. Wu F, Zhao S, Yu B, Chen YM, Wang W, Song ZG, et al. (March 2020). "A new coronavirus associated with human respiratory disease in China". *Nature*. **579** (7798): 265–269. Bibcode:2020Natur.579..265W. doi:10.1038/s41586-020-2008-3. PMC 7094943. PMID 32015508.
61. Chiara M, Horner DS, Gissi C, Pesole G (May 2021). "Comparative Genomics Reveals Early Emergence and Biased Spatiotemporal Distribution of SARS-CoV-2". *Molecular Biology and Evolution*. **38** (6): 2547–2565. doi:10.1093/molbev/msab049. PMC 7928790. PMID 33605421.
62. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. (March 2020). "A pneumonia outbreak associated with a new coronavirus of probable bat origin". *Nature*. **579** (7798): 270–273. Bibcode:2020Natur.579..270Z. doi:10.1038/s41586-020-2012-7. PMC 7095418. PMID 32015507.
63. Okada P, Buathong R, Phuygun S, Thanadachakul T, Parnmen S, Wongboot W, et al. (February 2020). "Early transmission patterns of coronavirus disease 2019 (COVID-19) in travellers from Wuhan to Thailand, January 2020". *Euro Surveillance*. **25** (8). doi:10.2807/1560-7917.ES.2020.25.8.2000097. PMC 7055038. PMID 32127124.
64. "Official hCoV-19 Reference Sequence". *www.gisaid.org*. Archived from the original on 6 May 2021. Retrieved 14 May 2021.
65. "The ancestor of SARS-CoV-2's Wuhan strain was circulating in late October 2019". *News Medical*. Archived from the original on 24 July 2021. Retrieved 10 May 2020. Journal reference: Kumar, S. et al. (2021). An evolutionary portrait...
66. "SARS-CoV-2 variants: risk assessment framework" (PDF). *GOV.UK*. Government Digital Service. Public Health England. 22 May 2021. GOV-8426. Archived (PDF) from the original on 27 May 2021. Retrieved 22 June 2021.
67. "Living Evidence – SARS-CoV-2 variants". Agency for Clinical Innovation. *nsw.gov.au*. Ministry of Health (New South Wales). 23 July 2021. Archived from the original on 16 April 2021. Retrieved 22 March 2021. Updated frequently.
68. "SARS-CoV-2 variants of concern". *ECDC.eu*. European Centre for Disease Prevention and Control. 30 April 2021. Archived from the original on 16 June 2021. Retrieved 12 May 2021. Updated frequently.
69. "Coronavirus Disease (COVID-19) Situation Reports". *who.int*. World Health Organization. Archived from the original on 26 January 2020. Retrieved 14 June 2021. Updated frequently.
70. "Investigation of SARS-CoV-2 variants: technical briefings". *GOV.UK*. Government Digital Service. Public Health England. Retrieved 18 November 2021. Updated frequently.
71. "Investigation of SARS-CoV-2 variants of concern: variant risk assessments". *GOV.UK*. Government Digital Service. Public Health England. Archived from the original on 19 June 2021. Retrieved 19 June 2021. Updated frequently.
72. *Weekly epidemiological update on COVID-19 – 20 July 2021* (Situation report). World Health Organization. 20 July 2021. Archived from the original on 23 July 2021. Retrieved 24 July 2021.
73. Planas D, Veyer D, Baidaliuk A, Staropoli I, Guivel-Benhassine F, Rajah MM, et al. (27 May 2021). "Reduced sensitivity of infectious SARS-CoV-2 variant B.1.617.2 to monoclonal antibodies and sera from convalescent and vaccinated individuals". bioRxiv 10.1101/2021.05.26.445838.
74. "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". World Health Organization. 26 November 2021. Retrieved 26 November 2021.
75. *Weekly epidemiological update on COVID-19 – 22 June 2021* (Situation report). World Health Organization. 22 June 2021. Archived from the original on 29 June 2021. Retrieved 26 June 2021.
76. *SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 10* (PDF) (Briefing). Public Health England. 7 May 2021. GOV-8226. Archived (PDF) from the original on 8 May 2021. Retrieved 6 June 2021.
77. Campbell F, Archer B, Laurenson-Schafer H, Jinnai Y, Konings F, Batra N, et al. (June 2021). "Increased transmissibility and global spread of SARS-CoV-2 variants of concern as at June 2021". *Euro Surveillance*. **26** (24): 2100509. doi:10.2807/1560-7917.ES.2021.26.24.2100509. PMC 8212592. PMID 34142653.
78. Sheikh A, McMenamin J, Taylor B, Robertson C (June 2021). "SARS-CoV-2 Delta VOC in Scotland: demographics, risk of hospital admission, and vaccine effectiveness". *Lancet*. **397** (10293): 2461–2462. doi:10.1016/S0140-6736(21)01358-1. PMC 8201647. PMID 34139198.
79. "SARS-CoV-2 variants of concern and variants under investigation in England Technical Briefing 21" (PDF). *Public Health England*. 20 August 2021. p. 16 and 22. Archived (PDF) from the original on 29 August 2021. Retrieved 29 August 2021.
80. *Risk assessment for SARS-CoV-2 variant Delta* (PDF) (Assessment). Public Health England. 23 July 2021. Archived (PDF) from the original on 25 July 2021. Retrieved 24 July 2021.
81. Yadav PD, Sapkal GN, Abraham P, Ella R, Deshpande G, Patil DY, et al. (May 2021). "Neutralization of variant under investigation B.1.617 with sera of BBV152 vaccinees". *Clinical Infectious Diseases*. **74** (ciab411). Oxford University Press: 366–368. bioRxiv 10.1101/2021.04.23.441101. doi:10.1093/cid/ciab411. PMID 33961693.
82. Callaway E (25 November 2021). "Heavily mutated coronavirus variant puts scientists on alert". *Nature*. **600** (7887): 21. Bibcode:2021Natur.600...21C. doi:10.1038/d41586-021-03552-w. PMID 34824381. S2CID 244660616.
83. *SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 29* (PDF) (Briefing). Public Health England. 26 November 2021. GOV-10481. Archived (PDF) from the original on 27 November 2021. Retrieved 26 November 2021.
84. *Risk assessment for SARS-CoV-2 variant Omicron* (PDF) (Assessment). Public Health England. 22 December 2021. GOV-10869. Retrieved 23 December 2021.
85. Nyberg T, Ferguson NM, Nash SG, Webster HH, Flaxman S, Andrews N, et al. (16 March 2022). "Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study". *The Lancet*. **399** (10332): 1303–1312. doi:10.1016/S0140-6736(22)00462-7. ISSN 0140-6736. PMC 8926413. PMID 35305296.
86. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. (18 December 2020). "Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations". *Virological*. Archived from the original on 21 December 2020. Retrieved 14 June 2021.
87. *Investigation of novel SARS-COV-2 variant, technical briefing 1* (PDF) (Briefing). Public Health England. 21 December 2020. Archived (PDF) from the original on 15 June 2021. Retrieved 6 June 2021.
88. Chand *et al.* (2020), p. 6, Potential impact of spike variant N501Y.
89. Nyberg T, Twohig KA, Harris RJ, Seaman SR, Flannagan J, Allen H, et al. (June 2021). "Risk of hospital admission for patients with SARS-CoV-2 variant B.1.1.7: cohort analysis". *BMJ*. **373**: n1412. arXiv:2104.05560. doi:10.1136/bmj.n1412. PMC 8204098. PMID 34130987. S2CID 235187479.
90. "Confirmed cases of COVID-19 variants identified in UK". *GOV.UK*. Public Health England. 15 January 2021. Archived from the original on 7 May 2021. Retrieved 5 March 2021.
91. Horby P, Barclay W, Gupta R, Huntley C (27 January 2021). *NERVTAG paper: note on variant P.1* (Note). Public Health England. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
92. Horby P, Barclay W, Huntley C (13 January 2021). *NERVTAG paper: brief note on SARS-CoV-2 variants* (Note). Public Health England. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
93. "Tracking SARS-CoV-2 variants". *www.who.int*. Retrieved 26 May 2022. Updated frequently.
94. "Covid: Ireland, Italy, Belgium and Netherlands ban flights from UK". *BBC News*. 20 December 2020. Archived from the original on 21 December 2020. Retrieved 23 December 2020.
95. Chand M, Hopkins S, Dabrera G, Achison C, Barclay W, Ferguson N, et al. (21 December 2020). Investigation of novel SARS-COV-2 variant: Variant of Concern 202012/01 (PDF) (Report). Public Health England. Archived (PDF) from the original on 22 February 2021. Retrieved 23 December 2020.
96. "PHE investigating a novel strain of COVID-19". Public Health England (PHE). 14 December 2020.
97. *Weekly epidemiological update on COVID-19 for 8 June 2021* (Situation report). World Health Organization. 8 June 2021. Archived from the original on 15 June 2021. Retrieved 14 June 2021.
98. Rambaut A, Loman N, Pybus O, Barclay W, Barrett J, Carabelli A, et al. (2020). Preliminary genomic characterisation of an emergent SARS-CoV-2 lineage in the UK defined by a novel set of spike mutations (Report). Written on behalf of COVID-19 Genomics Consortium UK. Archived from the original on 22 February 2021. Retrieved 20 December 2020.
99. Kupferschmidt K (20 December 2020). "Mutant coronavirus in the United Kingdom sets off alarms but its importance remains unclear". *Science Mag*. Archived from the original on 21 December 2020. Retrieved 21 December 2020.
100. Collier DA, De Marco A, Ferreira IA, Meng B, Datir RP, Walls AC, et al. (May 2021). "Sensitivity of SARS-CoV-2 B.1.1.7 to mRNA vaccine-elicited antibodies". *Nature* (Published). **593** (7857): 136–141. doi:10.1038/s41586-021-03412-7. PMC 7899479. PMID 33706364. We therefore generated pseudoviruses that carried the B.1.1.7 spike mutations with or without the additional E484K substitution and tested these against sera obtained after the first and second dose of the BNT162b2 mRNA vaccine as well as against convalescent sera. After the second vaccine dose, we observed a considerable loss of neutralising activity for the pseudovirus with the B.1.1.7 spike mutations and E484K (Fig. 3d, e). The mean fold change for the E484K-containing B.1.1.7 spike variant was 6.7 compared with 1.9 for the B.1.1.7 variant, relative to the wild-type spike protein (Fig. 3a–c and Extended Data Fig. 5). Similarly, when we tested a panel of convalescent sera with a range of neutralisation titres (Fig. 1f, g and Extended Data Fig. 5), we observed additional loss of activity against the mutant B.1.1.7 spike with E484K, with fold change of 11.4 relative to the wild-type spike protein (Fig. 3f, g and Extended Data Fig. 5).
101. "New evidence on VUI-202012/01 and review of the public health risk assessment". *Knowledge Hub*. 15 December 2020. Archived from the original on 21 December 2020. Retrieved 25 December 2020.
102. "COG-UK Showcase Event". 18 December 2020. Archived from the original on 14 June 2021. Retrieved 25 December 2020  via YouTube.
103. Davies NG, Abbott S, Barnard RC, Jarvis CI, Kucharski AJ, Munday JD, et al. (April 2021). "Estimated transmissibility and impact of SARS-CoV-2 lineage B.1.1.7 in England". *Science*. **372** (6538): eabg3055. doi:10.1126/science.abg3055. PMC 8128288. PMID 33658326.
104. Volz E, Mishra S, Chand M, Barrett JC, Johnson R, Geidelberg L, et al. (May 2021). "Assessing transmissibility of SARS-CoV-2 lineage B.1.1.7 in England". *Nature*. **593** (7858): 266–269. Bibcode:2021Natur.593..266V. doi:10.1038/s41586-021-03470-x. hdl:10044/1/87474. PMID 33767447.
105. Horby P, Huntley C, Davies N, Edmunds J, Ferguson N, Medley G, et al. (11 February 2021). "NERVTAG paper on COVID-19 variant of concern B.1.1.7: NERVTAG update note on B.1.1.7 severity (2021-02-11)" (PDF). *GOV.UK*. Archived (PDF) from the original on 13 April 2021. Retrieved 26 February 2021.
106. Gallagher J (22 January 2021). "Coronavirus: UK variant 'may be more deadly'". *BBC News*. Archived from the original on 23 May 2021. Retrieved 22 January 2021.
107. Frampton D, Rampling T, Cross A, Bailey H, Heaney J, Byott M, et al. (April 2021). "Genomic characteristics and clinical effect of the emergent SARS-CoV-2 B.1.1.7 lineage in London, UK: a whole-genome sequencing and hospital-based cohort study". *The Lancet. Infectious Diseases*. **21** (9): 1246–1256. doi:10.1016/S1473-3099(21)00170-5. PMC 8041359. PMID 33857406.
108. "PANGO lineages Lineage B.1.1.7". *cov-lineages.org*. 15 May 2021. Archived from the original on 16 June 2021. Retrieved 15 May 2021.
109. "Tracking SARS-CoV-2 variants (updated 2022-03-16)". *www.who.int*. 16 March 2022. Archived from the original on 17 March 2022. Retrieved 17 March 2022.
110. "Tracking SARS-CoV-2 variants (updated 2022-03-07)". *www.who.int*. 7 March 2022. Archived from the original on 15 March 2022. Retrieved 21 May 2022.
111. Mandavilli A (5 March 2021). "In Oregon, Scientists Find a Virus Variant With a Worrying Mutation – In a single sample, geneticists discovered a version of the coronavirus first identified in Britain with a mutation originally reported in South Africa". *The New York Times*. Archived from the original on 6 March 2021. Retrieved 6 March 2021.
112. Chen RE, Zhang X, Case JB, Winkler ES, Liu Y, VanBlargan LA, et al. (April 2021). "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies". *Nature Medicine*. **27** (4): 717–726. doi:10.1038/s41591-021-01294-w. PMC 8058618. PMID 33664494.
113. "B.1.1.7 Lineage with S:E484K Report". *outbreak.info*. 5 March 2021. Archived from the original on 7 March 2021. Retrieved 7 March 2021.
114. Moustafa AM, Bianco C, Denu L, Ahmed A, Neide B, Everett J, et al. (21 April 2021). "Comparative Analysis of Emerging B.1.1.7+E484K SARS-CoV-2 isolates from Pennsylvania". bioRxiv 10.1101/2021.04.21.440801.
115. "B.1.1.7 Lineage with S:E484K Report". *outbreak.info*. Archived from the original on 3 July 2021. Retrieved 28 May 2021.
116. *Risk related to the spread of new SARS-CoV-2 variants of concern in the EU/EEA – first update* (Risk assessment). European Centre for Disease Prevention and Control. 2 February 2021. Archived from the original on 25 March 2021. Retrieved 22 March 2021.
117. "South Africa announces a new coronavirus variant". *The New York Times*. 18 December 2020. Archived from the original on 21 December 2020. Retrieved 20 December 2020.
118. Wroughton L, Bearak M (18 December 2020). "South Africa coronavirus: Second wave fueled by new strain, teen 'rage festivals'". *The Washington Post*. Archived from the original on 27 December 2020. Retrieved 20 December 2020.
119. Mkhize Z (18 December 2020). "Update on Covid-19 (18th December 2020)" (Press release). South Africa. COVID-19 South African Online Portal. Archived from the original on 4 May 2021. Retrieved 23 December 2020. Our clinicians have also warned us that things have changed and that younger, previously healthy people are now becoming very sick.
120. Abdool Karim SS (19 December 2020). "The 2nd Covid-19 wave in South Africa:Transmissibility & a 501.V2 variant, 11th slide". www.scribd.com. Archived from the original on 6 January 2021. Retrieved 23 December 2020.
121. Lowe D (22 December 2020). "The New Mutations". *In the Pipeline*. American Association for the Advancement of Science. Archived from the original on 29 January 2021. Retrieved 23 December 2020. I should note here that there's another strain in South Africa that is bringing on similar concerns. This one has eight mutations in the Spike protein, with three of them (K417N, E484K and N501Y) that may have some functional role.
122. "Statement of the WHO Working Group on COVID-19 Animal Models (WHO-COM) about the UK and South African SARS-CoV-2 new variants" (PDF). World Health Organization. 22 December 2020. Archived (PDF) from the original on 4 May 2021. Retrieved 23 December 2020.
123. "Novel mutation combination in spike receptor binding site" (Press release). GISAID. 21 December 2020. Archived from the original on 22 February 2021. Retrieved 23 December 2020.
124. "Japan finds new coronavirus variant in travelers from Brazil". *Japan Today*. Japan. 11 January 2021. Archived from the original on 11 January 2021. Retrieved 14 January 2021.
125. Faria NR, Claro IM, Candido D, Moyses Franco LA, Andrade PS, Coletti TM, et al. (12 January 2021). "Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings". CADDE Genomic Network. *virological.org*. Archived from the original on 20 May 2021. Retrieved 23 January 2021.
126. "P.1". *cov-lineages.org*. Pango team. 1 July 2021. Archived from the original on 9 June 2021. Retrieved 7 March 2021.
127. "COG-UK Report on SARS-CoV-2 Spike mutations of interest in the UK" (PDF). *www.cogconsortium.uk*. Covid-19 Genomics UK Consortium. 15 January 2021. Archived (PDF) from the original on 16 April 2021. Retrieved 25 January 2021.
128. Voloch CM, da Silva Francisco R, de Almeida LG, Cardoso CC, Brustolini OJ, Gerber AL, et al. (March 2021). "Genomic characterization of a novel SARS-CoV-2 lineage from Rio de Janeiro, Brazil". *Journal of Virology*. **95** (10). doi:10.1128/jvi.00119-21. PMC 8139668. PMID 33649194.
129. Nascimento V, Souza V (25 February 2021). "COVID-19 epidemic in the Brazilian state of Amazonas was driven by long-term persistence of endemic SARS-CoV-2 lineages and the recent emergence of the new Variant of Concern P.1". *Research Square*. doi:10.21203/rs.3.rs-275494/v1. Archived from the original on 1 March 2021. Retrieved 2 March 2021.
130. Faria NR, Mellan TA, Whittaker C, Claro IM, Candido DD, Mishra S, et al. (May 2021). "Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil". *Science*. **372** (6544): 815–821. Bibcode:2021Sci...372..815F. doi:10.1126/science.abh2644. ISSN 0036-8075. PMC 8139423. PMID 33853970. Within this plausible region of parameter space, P.1 can be between 1.7 and 2.4 times more transmissible (50% BCI, 2.0 median, with a 99% posterior probability of being \>1) than local non-P1 lineages and can evade 21 to 46% (50% BCI, 32% median, with a 95% posterior probability of being able to evade at least 10%) of protective immunity elicited by previous infection with non-P.1 lineages, corresponding to 54 to 79% (50% BCI, 68% median) cross-immunity ... We estimate that infections are 1.2 to 1.9 times more likely (50% BCI, median 1.5, 90% posterior probability of being \>1) to result in mortality in the period after the emergence of P.1, compared with before, although posterior estimates of this relative risk are also correlated with inferred cross-immunity. More broadly, the recent epidemic in Manaus has strained the city's health care system, leading to inadequate access to medical care. We therefore cannot determine whether the estimated increase in relative mortality risk is due to P.1 infection, stresses on the Manaus health care system, or both. Detailed clinical investigations of P.1 infections are needed.
131. Andreoni M, Londoño E, Casado L (3 March 2021). "Brazil's Covid Crisis Is a Warning to the Whole World, Scientists Say – Brazil is seeing a record number of deaths, and the spread of a more contagious coronavirus variant that may cause reinfection". *The New York Times*. Archived from the original on 3 March 2021. Retrieved 3 March 2021.
132. Zimmer C (1 March 2021). "Virus Variant in Brazil Infected Many Who Had Already Recovered From Covid-19 – The first detailed studies of the so-called P.1 variant show how it devastated a Brazilian city. Now scientists want to know what it will do elsewhere". *The New York Times*. Archived from the original on 3 March 2021. Retrieved 3 March 2021.
133. Sofia Moutinho (4 May 2021). "Chinese COVID-19 vaccine maintains protection in variant-plagued Brazil". *Science*. doi:10.1126/science.abi9414. S2CID 234804602. Archived from the original on 16 June 2021. Retrieved 4 May 2021.
134. Gaier R (5 March 2021). "Exclusive: Oxford study indicates AstraZeneca effective against Brazil variant, source says". *Reuters*. Rio de Janeiro. Archived from the original on 9 March 2021. Retrieved 9 March 2021.
135. "Exclusive: Oxford study indicates AstraZeneca effective against Brazil variant, source says". *Reuters*. Rio de Janeiro. 8 March 2021. Archived from the original on 9 March 2021. Retrieved 9 March 2021.
136. Simões E, Gaier R (8 March 2021). "CoronaVac e Oxford são eficazes contra variante de Manaus, dizem laboratórios" \[CoronaVac and Oxford are effective against Manaus variant, say laboratories\]. *UOL Notícias* (in Portuguese). Reuters Brazil. Archived from the original on 8 March 2021. Retrieved 9 March 2021.
137. "Delta Globally Dominant Covid Strain, Now Spread To 185 Countries: WHO". 22 September 2021.
138. "PANGO lineages". *cov-lineages.org*. Archived from the original on 3 June 2021. Retrieved 18 April 2021.
139. Koshy J (8 April 2021). "Coronavirus | Indian 'double mutant' strain named B.1.617". *The Hindu*. Archived from the original on 26 May 2021. Retrieved 10 April 2021.
140. "India's variant-fuelled second wave coincided with spike in infected flights landing in Canada". Toronto Sun. 10 April 2021. Archived from the original on 2 June 2021. Retrieved 10 April 2021.
141. "Weekly epidemiological update on COVID-19". *World Health Organization*. 11 May 2021. Archived from the original on 11 May 2021. Retrieved 12 May 2021.
142. "COVID strain first detected in India found in 53 territories: WHO". *www.aljazeera.com*. Archived from the original on 19 June 2021. Retrieved 27 May 2021.
143. Mishra S, Mindermann S, Sharma M, Whittaker C, Mellan TA, Wilton T, et al. (1 September 2021). "Changing composition of SARS-CoV-2 lineages and rise of Delta variant in England". *eClinicalMedicine*. **39**: 101064. doi:10.1016/j.eclinm.2021.101064. ISSN 2589-5370. PMC 8349999. PMID 34401689.
144. "British scientists warn over Indian coronavirus variant". *Reuters*. 7 May 2021. Archived from the original on 22 May 2021. Retrieved 7 May 2021.
145. "expert reaction to VUI-21APR-02/B.1.617.2 being classified by PHE as a variant of concern". *Science Media Centre*. 7 May 2021. Archived from the original on 13 July 2021. Retrieved 15 May 2021.
146. *SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 14* (PDF) (Briefing). Public Health England. 3 June 2021. GOV-8530. Archived (PDF) from the original on 4 July 2021. Retrieved 26 June 2021.
147. Pearson H, Pullen L, Dao C (11 June 2021). "AHS breaks down vaccination data of COVID-19 Delta variant outbreak at Calgary hospital". *Global News*. Archived from the original on 12 June 2021. Retrieved 12 June 2021.
148. Schraer R (4 June 2021). "'Nepal variant': What's the mutation stopping green list trips to Portugal?". *BBC News*. Archived from the original on 19 June 2021. Retrieved 18 June 2021.
149. Acharya B, Jamkhandikar S (23 June 2021). "Explainer: What is the Delta variant of coronavirus with K417N mutation?". *Reuters*. Archived from the original on 23 June 2021. Retrieved 23 June 2021.
150. *SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 17* (PDF) (Briefing). Public Health England. 25 June 2021. GOV-8576. Archived (PDF) from the original on 25 June 2021. Retrieved 26 June 2021.
151. Sharma M (14 June 2021). "New 'Delta Plus' variant of SARS-CoV-2 identified; here's what we know so far". *India Today*. Archived from the original on 17 June 2021. Retrieved 16 June 2021.
152. Cutler S (18 June 2021). "'Nepal variant': what we've learned so far". *The Conversation*. Archived from the original on 18 June 2021. Retrieved 18 June 2021.
153. Tang JW, Oliver T (2021). "Introduction of the South African SARS-CoV-2 variant 501Y.V2 into the UK". *The Journal of Infection*. **82** (4): e8–e10. doi:10.1016/j.jinf.2021.01.007. PMC 7813514. PMID 33472093.
154. "India says new COVID variant is a concern". *Reuters*. Bengaluru. 22 June 2021. Archived from the original on 23 June 2021. Retrieved 23 June 2021.
155. Biswas S (23 June 2021). "Delta plus: Scientists say too early to tell risk of Covid-19 variant". *BBC News*. Archived from the original on 23 June 2021. Retrieved 23 June 2021.
156. Roberts M (19 October 2021). "Covid-19: New mutation of Delta variant under close watch in UK". *www.bbc.co.uk*. Retrieved 19 October 2021.
157. "Tracking SARS-CoV-2 variants". *www.who.int*. 7 June 2022. Archived from the original on 22 June 2022. Retrieved 23 June 2022.
158. "Southern California COVID-19 Strain Rapidly Expands Global Reach". *Cedars-Sinai Newsroom*. Los Angeles. 11 February 2021. Archived from the original on 16 April 2021. Retrieved 17 March 2021.
159. Latif AA, Mullen JL, Alkuzweny M, Tsueng G, Cano M, Haag E, et al. (The Center for Viral Systems Biology). "B.1.429 Lineage Report". *outbreak.info*. Archived from the original on 3 July 2021. Retrieved 28 May 2021.
160. "New California Variant May Be Driving Virus Surge There, Study Suggests". *The New York Times*. 19 January 2021. Archived from the original on 9 June 2021. Retrieved 20 January 2021.
161. Azad A (17 March 2021). "Coronavirus strains first detected in California are officially 'variants of concern,' CDC says". *CNN*. Archived from the original on 6 June 2021. Retrieved 6 June 2021.
162. Shen X, Tang H, Pajon R, Smith G, Glenn GM, Shi W, et al. (June 2021). "Neutralization of SARS-CoV-2 Variants B.1.429 and B.1.351". *The New England Journal of Medicine*. **384** (24): 2352–2354. doi:10.1056/NEJMc2103740. PMC 8063884. PMID 33826819.
163. "SARS-CoV-2 Variant Classifications and Definitions: Updated June 23, 2021". *CDC.gov*. Centers for Disease Control and Prevention. 23 June 2021. Archived from the original on 29 June 2021.
164. Zimmer C, Mandavilli A (14 May 2021). "How the United States Beat the Variants, for Now". *The New York Times*. Archived from the original on 16 May 2021. Retrieved 17 May 2021.
165. Wadman M (23 February 2021). "California coronavirus strain may be more infectious – and lethal". *Science News*. doi:10.1126/science.abh2101. Archived from the original on 1 May 2021. Retrieved 17 March 2021.
166. Ho C (28 February 2021). "Do coronavirus tests work on variants?". *San Francisco Chronicle*. Archived from the original on 24 June 2021. Retrieved 24 June 2021.
167. "Local COVID-19 Strain Found in Over One-Third of Los Angeles Patients". *news wise* (Press release). California: Cedars Sinai Medical Center. 19 January 2021. Archived from the original on 13 June 2021. Retrieved 3 March 2021.
168. "B.1.429". *Rambaut Group, University of Edinburgh*. PANGO Lineages. 15 February 2021. Archived from the original on 28 April 2021. Retrieved 16 February 2021.
169. "B.1.429 Lineage Report". *Scripps Research*. outbreak.info. 15 February 2021. Archived from the original on 9 June 2021. Retrieved 16 February 2021.
170. "COVID-19 Variant First Found in Other Countries and States Now Seen More Frequently in California". *California Department of Public Health*. Archived from the original on 16 June 2021. Retrieved 30 January 2021.
171. Weise E, Weintraub K. "New strains of COVID swiftly moving through the US need careful watch, scientists say". *USA Today*. Archived from the original on 4 March 2021. Retrieved 30 January 2021.
172. "Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: preliminary findings". *Virological*. 12 January 2021. Retrieved 26 June 2021.
173. Ranzani O (2021). "Effectiveness of the CoronaVac vaccine in the elderly population during a Gamma variant-associated epidemic of COVID-19 in Brazil". medRxiv 10.1101/2021.05.19.21257472v3.
174. "Tracking SARS-CoV-2 variants". *who.int*. World Health Organization.
175. "Delta-PCR-testen" \[The Delta PCR Test\] (in Danish). Statens Serum Institut. 25 February 2021. Archived from the original on 7 February 2021. Retrieved 27 February 2021.
176. "GISAID hCOV19 Variants (see menu option 'G/484K.V3 (B.1.525)')". *GISAID*. Archived from the original on 23 June 2021. Retrieved 4 March 2021.
177. "Status for udvikling af SARS-CoV-2 Variants of Concern (VOC) i Danmark" \[Status of development of SARS-CoV-2 Variants of Concern (VOC) in Denmark\] (in Danish). Statens Serum Institut. 27 February 2021. Archived from the original on 27 August 2021. Retrieved 27 February 2021.
178. "B.1.525 international lineage report". *cov-lineages.org*. Pango team. 19 May 2021. Archived from the original on 9 June 2021. Retrieved 16 February 2021.
179. Roberts M (16 February 2021). "Another new coronavirus variant seen in the UK". *BBC News*. Archived from the original on 20 June 2021. Retrieved 16 February 2021.
180. "DOH confirms detection of 2 SARS-CoV-2 mutations in Region 7". *ABS-CBN News*. 18 February 2021. Archived from the original on 3 May 2021. Retrieved 13 March 2021.
181. Santos E (13 March 2021). "DOH reports COVID-19 variant 'unique' to PH, first case of Brazil variant". *CNN Philippines*. Archived from the original on 16 March 2021. Retrieved 17 March 2021.
182. "DOH confirms new COVID-19 variant first detected in PH, first case of Brazil variant". *ABS-CBN News*. 13 March 2021. Archived from the original on 2 May 2021. Retrieved 13 March 2021.
183. "PH discovered new COVID-19 variant earlier than Japan, expert clarifies". *CNN Philippines*. 13 March 2021. Archived from the original on 17 March 2021. Retrieved 17 March 2021.
184. "Japan detects new coronavirus variant from traveler coming from PH". *CNN Philippines*. 13 March 2021. Archived from the original on 16 March 2021. Retrieved 21 March 2021.
185. "UK reports 2 cases of COVID-19 variant first detected in Philippines". *ABS-CBN*. 17 March 2021. Archived from the original on 18 March 2021. Retrieved 21 March 2021.
186. "Covid-19: Sarawak detects variant reported in the Philippines". 30 April 2021. Archived from the original on 1 May 2021. Retrieved 30 April 2021.
187. "Tracking SARS-CoV-2 variants". *www.who.int*. Retrieved 1 June 2021.
188. Barton MI, MacGowan SA, Kutuzov MA, Dushek O, Barton GJ, van der Merwe PA (26 August 2021). Fouchier RA, Van der Meer JW, Fouchier RA (eds.). "Effects of common mutations in the SARS-CoV-2 Spike RBD and its ligand, the human ACE2 receptor on binding affinity and kinetics". *eLife*. **10**: e70658. doi:10.7554/eLife.70658. ISSN 2050-084X. PMC 8480977. PMID 34435953.
189. SARS-CoV-2 sequences by variant, Jul 26, 2021, USA Our World in Data
190. "Tracking SARS-CoV-2 variants". *www.who.int*. 31 May 2021. Retrieved 5 June 2021.
191. "Weekly epidemiological update on COVID-19 - 27 April 2021" (PDF). *World Health Organization*. 27 April 2021. Retrieved 6 June 2021.
192. Le Page M (4 June 2021). "Indian covid-19 variant (B.1.617)". *New Scientist*. Retrieved 8 June 2021.
193. It was considered a previously circulating variant of interest by the World Health Organization on March 2022.SARS-CoV-2 variants of concern and variants under investigation in England - Technical briefing 10 (PDF) (Report). London. 7 May 2021. Retrieved 5 June 2021. *A variant first detected in India was designated under investigation on 1 April 2021 as VUI-21APR-01 (B.1.617.1).* `{{cite report}}`: Unknown parameter `|agency=` ignored (help)  This article incorporates text published under the British Open Government Licence v3.0:
194. "Tracking SARS-CoV-2 variants". *World Health Organization*. Retrieved 17 June 2021.
195. "Weekly epidemiological update on COVID-19 - 15 June 2021" (PDF) (44 ed.). World Health Organization. 15 June 2021. Retrieved 16 August 2021. Lambda has been associated with substantive rates of community transmission in multiple countries, with rising prevalence over time concurrent with increased COVID-19 incidence. The earliest sequenced samples were reported from Peru in August 2020.
196. "Tracking SARS-CoV-2 variants". *who.int*. World Health Organization. Updated frequently.
197. "Tracking SARS-CoV-2 variants (updated 2022-03-16)". *www.who.int*. 16 March 2022. Archived from the original on 17 March 2022. Retrieved 17 March 2022.
198. "Tracking SARS-CoV-2 variants (updated 2022-03-07)". *www.who.int*. 7 March 2022. Archived from the original on 15 March 2022. Retrieved 21 May 2022.
199. "Tracking SARS-CoV-2 variants". *who.int*. World Health Organization. Archived from the original on 18 June 2021. Retrieved 1 September 2021.
200. "Tracking SARS-CoV-2 variants (updated 2022-03-16)". *www.who.int*. 16 March 2022. Archived from the original on 17 March 2022. Retrieved 17 March 2022.
201. "Tracking SARS-CoV-2 variants (updated 2022-03-07)". *www.who.int*. 7 March 2022. Archived from the original on 15 March 2022. Retrieved 21 May 2022.
202. "Classification of Omicron (B.1.1.529): SARS-CoV-2 Variant of Concern". *www.who.int*. Retrieved 26 November 2021.
203. Callaway E (25 November 2021). "Heavily mutated coronavirus variant puts scientists on alert". *Nature*. **600** (7887): 21. Bibcode:2021Natur.600...21C. doi:10.1038/d41586-021-03552-w. PMID 34824381. S2CID 244660616.
204. Fernando MJ. "World experts hold special meeting on worrying new COVID-19 variant in South Africa: Latest updates". *USA Today*.
205. "outbreak.info". *outbreak.info*. Retrieved 26 November 2021.
206. "Covid: New heavily mutated variant B.1.1.529 in South Africa raises concern". *BBC News*. 25 November 2021. Retrieved 25 November 2021.
207. Whiteside P (30 November 2021). "COVID-19: How the spread of Omicron went from patient zero to all around the globe". *Sky News*. Retrieved 3 January 2022.
208. @BNODesk (26 November 2021). "Statement from Israel's health ministry reporting 1 confirmed case of new coronavirus variant B.1.1.529" (Tweet). Retrieved 26 November 2021  via Twitter.
209. "14:30 4 מאומתים לווריאנט החדש התגלו בארץ, רה"מ יקיים מסיבת עיתונאים" \["...Verified for the new strain 4 verified for the new variant were discovered in the country..."\]. *m.ynet.co.il*. Retrieved 26 November 2021.
210. "Belgium detects first case of new COVID-19 variant in Europe". *Reuters*. 26 November 2021. Retrieved 26 November 2021.
211. "INSACOG WEEKLY BULLETIN" (PDF). *dbtindia.gov.in*. 10 January 2022. Retrieved 24 January 2022.
212. "Statement on Omicron sublineage BA.2". *www.who.int*. Retrieved 4 April 2022.
213. Schmidt C. "What We Know About Omicron's BA.2 Variant So Far". *Scientific American*. Retrieved 4 April 2022.
214. "Covid infections rising again across UK - ONS". *BBC News*. 11 March 2022.
215. Jessica Rendall (29 March 2022). "BA.2 is Now the Dominant COVID Variant in US, CDC Data Shows".
216. ECDC (12 May 2022). "Changes to list of SARS-CoV-2 variants of concern, variants of interest, and variants under monitoring" (PDF).
217. Peter Russell (6 January 2023). "Omicron XBB.1.5: What Do We Know So Far?". Retrieved 8 January 2023.
218. Johnson A. "What We Know About 'Eris' Covid Variant EG.5: The Dominant Strain Driving An Uptick In Cases". *Forbes*. Retrieved 11 August 2023.
219. "cov-lineages.org". Retrieved 11 August 2023.
220. Mundasad S (10 August 2023). "What we know about the Covid variant EG.5 dubbed 'Eris'". *BBC News*. BBC. Retrieved 10 August 2023.
221. "SARS-CoV-2 genome sequence prevalence and growth rate update: 8 November 2023". *GOV.UK*. 6 December 2023. Retrieved 21 December 2023.
222. "COVID-19 Weekly Epidemiological Update (Edition 156 published 17 August 2023)" (PDF). World Health Organization. 17 August 2023. Retrieved 30 August 2023.
223. "Covid: Everything we know about the new Omicron descendant as winter flu surges". *The Independent*. 8 December 2023. Retrieved 16 December 2023.
224. Bartel A, Grau JH, Bitzegeio J, Werber D, Linzner N, Schumacher V, et al. (10 January 2024). "Timely Monitoring of SARS-CoV-2 RNA Fragments in Wastewater Shows the Emergence of JN.1 (BA.2.86.1.1, Clade 23I) in Berlin, Germany". *Viruses*. **16** (1): 102. doi:10.3390/v16010102. ISSN 1999-4915. PMC 10818819. PMID 38257802.
225. "Initial Risk Evaluation of JN.1, 19 December 2023" (PDF). World Health Organization. 19 December 2023. Retrieved 11 January 2024.
226. "Return of the mask? Singapore, Indonesia bring back limits as Covid cases jump". *mint*. 14 December 2023. Retrieved 16 December 2023.
227. "COVID-19 Activity Increases as Prevalence of JN.1 Variant Continues to Rise". Centers for Disease Control and Prevention. 5 January 2024. Retrieved 11 January 2024.
228. *Updated Risk Evaluation of JN.1, 09 January 2023 \[mislabelled date\]* (PDF), World Health Organization, 9 February 2024, Wikidata Q124477897, archived (PDF) from the original on 10 February 2024
229. Leventis Lourgos A (9 May 2024). "New COVID 'FLiRT' variants are spreading nationwide. Chicago health experts urge up to date vaccination". *Yahoo News*. Retrieved 14 May 2024  via Chicago Tribune.
230. Kee C (20 May 2024). "The new COVID variants spreading in the US are called 'FLiRT.' But why?". *TODAY.com*. Retrieved 29 May 2024.
231. Nathan Bartlett (9 July 2024). "From FLiRT to FLuQE: what to know about the latest COVID variants on the rise". *The Conversation*. Wikidata Q127329080. Archived from the original on 10 July 2024.
232. Lin II RG (30 August 2024). "An even more contagious COVID strain is 'just getting started' amid California wave". *Los Angeles Times*. Retrieved 1 September 2024.
233. Michelle Roberts (16 September 2024). "New XEC Covid variant starting to spread". *www.bbc.com*. Retrieved 16 September 2024.
234. *Tracking SARS-CoV-2 variants*, World Health Organization, 29 May 2022, Wikidata Q127329189, archived from the original on 29 May 2022
235. *Tracking SARS-CoV-2 variants*, World Health Organization, 11 February 2023, Wikidata Q127329489, archived from the original on 11 February 2023
236. *Tracking SARS-CoV-2 variants*, World Health Organization, 28 June 2024, Wikidata Q127328784, archived from the original on 10 July 2024
237. "Detection of SARS-CoV-2 P681H Spike Protein Variant in Nigeria". *Virological*. 23 December 2020. Archived from the original on 13 June 2021. Retrieved 1 January 2021.
238. "Lineage B.1.1.207". *cov-lineages.org*. Pango team. Archived from the original on 27 January 2021. Retrieved 11 March 2021.
239. "Queensland travellers have hotel quarantine extended after Russian variant of coronavirus detected". *www.abc.net.au*. 3 March 2021. Archived from the original on 3 March 2021. Retrieved 3 March 2021.
240. Koshy J (21 April 2021). "New coronavirus variant found in West Bengal". *www.thehindu.com*. Archived from the original on 26 May 2021. Retrieved 23 April 2021.
241. "What is the new 'triple mutant variant' of Covid-19 virus found in Bengal? How bad is it?". *www.indiatoday.in*. 22 April 2021. Archived from the original on 28 April 2021. Retrieved 23 April 2021.
242. "PANGO lineages Lineage B.1.618". *cov-lineages.org*. Archived from the original on 14 May 2021. Retrieved 23 April 2021.
243. "Detecting novel SARS-CoV-2 variants in New York City wastewater". *University of Missouri*. Retrieved 10 March 2022.
244. Smyth DS, Trujillo M, Gregory DA, Cheung K, Gao A, Graham M, et al. (3 February 2022). "Tracking cryptic SARS-CoV-2 lineages detected in NYC wastewater". *Nature Communications*. **13** (1): 635. Bibcode:2022NatCo..13..635S. doi:10.1038/s41467-022-28246-3. ISSN 2041-1723. PMC 8813986. PMID 35115523.
245. Browne E (4 January 2022). "What we know about "IHU" COVID variant B.1.640.2 with 46 mutations". *Newsweek*. Archived from the original on 5 January 2022. Retrieved 5 January 2022.
246. Freund A (7 January 2022). "Coronavirus: Health experts not alarmed by variant identified in France". *Deutsche Welle*. Archived from the original on 7 January 2022. Retrieved 8 January 2022.
247. Freund A (4 January 2022). "New coronavirus variant identified in France". *Deutsche Welle*. Archived from the original on 5 January 2022. Retrieved 5 January 2022.
248. Bengali S (5 January 2022). "A variant found in France is not a concern, the W.H.O. says". *The New York Times*. ISSN 0362-4331. Archived from the original on 6 January 2022. Retrieved 5 January 2022.
249. "Tracking SARS-CoV-2 variants". *World Health Organization*. Archived from the original on 25 November 2021. Retrieved 5 January 2022.
250. Cobbe E (6 January 2022). "'IHU' coronavirus variant 'on our radar' but not a threat, World Health Organization says". *CBS News*. Archived from the original on 7 January 2022. Retrieved 8 January 2022.
251. Chaturvedi A (4 January 2022). "New Covid-19 variant 'IHU' discovered in France, has more mutations than Omicron". *Hindustan Times*. Archived from the original on 5 January 2022. Retrieved 5 January 2022.
252. "COVID-19: New variant, B.1.640.2, detected in France – study". *The Jerusalem Post*. Archived from the original on 4 January 2022. Retrieved 4 January 2022.
253. "What is the Deltacron variant of Covid and where has it been found?". *The Guardian*. 11 March 2022. Retrieved 18 April 2022.
254. Lapid N (9 March 2022). "Variant that combines Delta and Omicron identified; dogs sniff out virus with high accuracy". *Reuters*. Retrieved 18 April 2022.
255. "COVID-19, Ukraine & Other Global Health Emergencies Virtual Press conference transcript - 16 March 2022". *www.who.int*. Retrieved 24 April 2022.
256. Snider M. "There may be a new COVID variant, Deltacron. Here's what we know about it". *USA TODAY*. Retrieved 24 April 2022.
257. Colson P, Fournier PE, Delerce J, Million M, Bedotto M, Houhamdi L, et al. (16 March 2022). "Culture and identification of a "Deltamicron" SARS-CoV-2 in a three cases cluster in southern France". pp. 3739–3749. medRxiv 10.1101/2022.03.03.22271812v2.
258. "Delta (AY.4) and BA.1 recombinant in France/Denmark \[~30 seqs, isolated/passaged in Vero\] · Issue #444 · cov-lineages/pango-designation". *GitHub*. Retrieved 24 April 2022.
259. O'Neill L (21 March 2022). "Deltacron: what scientists know so far about this new hybrid coronavirus". *The Conversation*. Retrieved 18 April 2022.
260. Sundaravelu A (28 July 2023). "Scientists find 'most mutated' and 'most extreme' Covid variant ever in patient". Metro News. Retrieved 28 July 2023.
261. "SARS-CoV-2 variants of concern and variants under investigation in England : Technical briefing 39" (PDF). *gov.uk*. UK Health Security Agency. 25 March 2022. Archived (PDF) from the original on 4 April 2022. Retrieved 6 April 2022.
262. "COVID-19 Weekly Epidemiological Update : Edition 84, published 22 March 2022" (PDF). *who.int*. World Health Organization. 2 March 2022. Retrieved 6 April 2022.
263. "Cov-Lineages". *cov-lineages.org*. Retrieved 6 April 2022.
264. Kupferschmidt K (23 December 2020). "U.K. variant puts spotlight on immunocompromised patients' role in the COVID-19 pandemic". *Science*. doi:10.1126/science.abg2911. S2CID 234378594. Archived from the original on 24 June 2021. Retrieved 25 February 2021.
265. Sutherland S (23 February 2021). "COVID Variants May Arise in People with Compromised Immune Systems". *Scientific American*. Archived from the original on 6 June 2021. Retrieved 25 February 2021.
266. McCarthy KR, Rennick LJ, Nambulli S, Robinson-McCarthy LR, Bain WG, Haidar G, et al. (March 2021). "Recurrent deletions in the SARS-CoV-2 spike glycoprotein drive antibody escape". *Science*. **371** (6534): 1139–1142. Bibcode:2021Sci...371.1139M. doi:10.1126/science.abf6950. PMC 7971772. PMID 33536258.
267. "新型コロナウイルス変異株とは | 日本医学臨床検査研究所" \[What is the novel coronavirus mutation | Japan Medical Laboratory Laboratory\]. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
268. "Variant: 21G (Lambda)". *CoVariants*. Archived from the original on 21 July 2021. Retrieved 3 September 2021.
269. Frank Diamond (7 August 2021). "More Data Point to Lambda Variant's Potential Lethality". *Infection Control Today*. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
270. Kimura I, Kosugi Y, Wu J, Yamasoba D, Butlertanaka EP, Tanaka YL, et al. (2021). "SARS-CoV-2 Lambda variant exhibits higher infectivity and immune resistance". *Cell Reports*. **38** (2): 110218. bioRxiv 10.1101/2021.07.28.454085. doi:10.1016/j.celrep.2021.110218. hdl:2433/267436. PMC 8683271. PMID 34968415. S2CID 236520241. Archived from the original on 16 September 2021. Retrieved 3 September 2021.
271. Greenwood M (15 January 2021). "What Mutations of SARS-CoV-2 are Causing Concern?". *News Medical Lifesciences*. Archived from the original on 16 January 2021. Retrieved 16 January 2021.
272. Tandel D, Gupta D, Sah V, Harshan KH (30 April 2021). "N440K variant of SARS-CoV-2 has Higher Infectious Fitness". bioRxiv 10.1101/2021.04.30.441434.
273. Bhattacharjee S (3 May 2021). "COVID-19 | A.P. strain at least 15 times more virulent". *The Hindu*. Archived from the original on 10 May 2021. Retrieved 4 May 2021.
274. "N440k Covid Variant: Mutant N440K 10 times more infectious than parent strain | Hyderabad News". *The Times of India*. 2 May 2021. Archived from the original on 30 August 2021. Retrieved 3 September 2021.
275. "感染・伝播性の増加や抗原性の変化が懸念される 新型コロナウイルス(SARS-CoV-2)の新規変異株について (第13報)" \[New Mutant Strains of the Novel Coronavirus (SARS-CoV-2) Concerned About Increased Infectivity and Transmissibility and Changes in Antigenicity (13th Report)\]. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
276. "Mutations in spike putatively linked to outbreak at Danish mink farms". *GISAID*. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
277. "University of Graz". *www.uni-graz.at*. Archived from the original on 6 May 2021. Retrieved 22 February 2021.
278. "Coronavirus SARS-CoV-2 (formerly known as Wuhan coronavirus and 2019-nCoV) – what we can find out on a structural bioinformatics level". *Innophore*. 23 January 2020. Retrieved 22 February 2021.
279. Singh A, Steinkellner G, Köchl K, Gruber K, Gruber CC (February 2021). "Serine 477 plays a crucial role in the interaction of the SARS-CoV-2 spike protein with the human receptor ACE2". *Scientific Reports*. **11** (1): 4320. Bibcode:2021NatSR..11.4320S. doi:10.1038/s41598-021-83761-5. PMC 7900180. PMID 33619331.
280. "BioNTech: We aspire to individualize cancer medicine". *BioNTech*. Archived from the original on 18 June 2021. Retrieved 22 February 2021.
281. Schroers B, Gudimella R, Bukur T, Roesler T, Loewer M, Sahin U (4 February 2021). "Large-scale analysis of SARS-CoV-2 spike-glycoprotein mutants demonstrates the need for continuous screening of virus isolates". bioRxiv 10.1101/2021.02.04.429765.
282. "People Are Talking About A 'Double Mutant' Variant In India. What Does That Mean?". *NPR*. Archived from the original on 27 April 2021. Retrieved 27 April 2021. ...scientifically, the term "double mutant" makes no sense, Andersen says. "SARS-CoV-2 mutates all the time. So there are many double mutants all over the place. The variant in India really shouldn't be called that."
283. Mandavilli A, Mueller B (2 March 2021). "Why Virus Variants Have Such Weird Names". *The New York Times*. ISSN 0362-4331. Archived from the original on 20 June 2021. Retrieved 2 March 2021.
284. "escape mutation". HIV i-Base. 11 October 2012. Archived from the original on 9 May 2021. Retrieved 19 February 2021.
285. Wise J (February 2021). "Covid-19: The E484K mutation and the risks it poses". *BMJ*. **372**: n359. doi:10.1136/bmj.n359. PMID 33547053. S2CID 231821685.
286. "Brief report: New Variant Strain of SARS-CoV-2 Identified in Travelers from Brazil" (PDF) (Press release). Japan: NIID (National Institute of Infectious Diseases). 12 January 2021. Archived (PDF) from the original on 15 January 2021. Retrieved 14 January 2021.
287. *Investigation of novel SARS-CoV-2 variant 202012/01, technical briefing 5* (PDF) (Briefing). Public Health England. 2 February 2021. GW-1905. Archived (PDF) from the original on 29 June 2021. Retrieved 14 June 2021.
288. Greaney AJ, Loes AN, Crawford KH, Starr TN, Malone KD, Chu HY, et al. (March 2021). "Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies". *Cell Host & Microbe*. **29** (3): 463–476.e6. doi:10.1016/j.chom.2021.02.003. PMC 7869748. PMID 33592168.
289. Kupferschmidt K (January 2021). "New mutations raise specter of 'immune escape'". *Science*. **371** (6527): 329–330. Bibcode:2021Sci...371..329K. doi:10.1126/science.371.6527.329. PMID 33479129.
290. Rettner R (2 February 2021). "UK coronavirus variant develops vaccine-evading mutation – In a handful of instances, the U.K. coronavirus variant has developed a mutation called E484K, which may impact vaccine effectiveness". *Live Science*. Archived from the original on 2 February 2021. Retrieved 2 February 2021.
291. Achenbach J, Booth W (2 February 2021). "Worrisome coronavirus mutation seen in U.K. variant and in some U.S. samples". *The Washington Post*. Archived from the original on 2 February 2021. Retrieved 2 February 2021.
292. "東京五輪で"最凶"の「ラムダ株」が上陸 ワクチン効果は5分の1?" \["Lambda strain" landed at the Tokyo Olympics, and the vaccine effect is one-fifth?\]. *gooニュース*. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
293. "The Lambda variant: is it more infectious, and can it escape vaccines? A virologist explains". *The Conversation*. 21 July 2021. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
294. COG-UK update on SARS-CoV-2 Spike mutations of special interest: Report 1 (PDF) (Report). COVID-19 Genomics UK Consortium (COG-UK). 20 December 2020. p. 7. Archived from the original (PDF) on 25 December 2020. Retrieved 31 December 2020.
295. "Researchers Discover New Variant of COVID-19 Virus in Columbus, Ohio". *wexnermedical.osu.edu*. 13 January 2021. Archived from the original on 15 January 2021. Retrieved 16 January 2021.
296. Tu H, Avenarius MR, Kubatko L, Hunt M, Pan X, Ru P, et al. (26 January 2021). "Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y in Clinical Samples in Columbus Ohio". bioRxiv 10.1101/2021.01.12.426407.
297. "新たな変異ある「デルタ株」検出 感染力への影響分からず" \[Detection of a new mutant "Delta strain" The effect on infectivity is unknown\]. *NHKニュース*. 31 August 2021. Archived from the original on 1 September 2021. Retrieved 2 September 2021.
298. "「N501S 変異を有する新たなデルタ株(B.1.617.2 系統)の市中感染事例(国内第1例目)を確認」 〜医科歯科大 新型コロナウイルス全ゲノム解析プロジェクト 第8報〜" \["Confirmed a case of community-acquired infection (first case in Japan) of a new delta strain (B.1.617.2 strain) with N501S mutation" -Medical and Dental University New Coronavirus Whole Genome Analysis Project 8th Report-\] (PDF). Archived (PDF) from the original on 30 August 2021. Retrieved 2 September 2021.
299. Maison DP, Ching LL, Shikuma CM, Nerurkar VR (January 2021). "Genetic Characteristics and Phylogeny of 969-bp S Gene Sequence of SARS-CoV-2 from Hawaii Reveals the Worldwide Emerging P681H Mutation". bioRxiv 10.1101/2021.01.06.425497.  Available under CC BY 4.0 Archived 16 October 2017 at the Wayback Machine.
300. Corum J, Zimmer C (9 February 2021). "Coronavirus Variant Tracker". *The New York Times*. Archived from the original on 30 November 2021. Retrieved 1 December 2021. Constantly Updated
301. Schraer R (18 July 2020). "Coronavirus: Are mutations making it more infectious?". *BBC News*. Archived from the original on 30 December 2020. Retrieved 3 January 2021.
302. "New, more infectious strain of COVID-19 now dominates global cases of virus: study". *medicalxpress.com*. Archived from the original on 17 November 2020. Retrieved 16 August 2020.
303. Korber B, Fischer WM, Gnanakaran S, Yoon H, Theiler J, Abfalterer W, et al. (August 2020). "Tracking Changes in SARS-CoV-2 Spike: Evidence that D614G Increases Infectivity of the COVID-19 Virus". *Cell*. **182** (4): 812–827.e19. doi:10.1016/j.cell.2020.06.043. PMC 7332439. PMID 32697968.
304. Hou YJ, Chiba S, Halfmann P, Ehre C, Kuroda M, Dinnon KH, et al. (December 2020). "SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo". *Science*. **370** (6523): 1464–1468. Bibcode:2020Sci...370.1464H. doi:10.1126/science.abe8499. PMC 7775736. PMID 33184236. an emergent Asp614→Gly (D614G) substitution in the spike glycoprotein of SARS-CoV-2 strains that is now the most prevalent form globally
305. Volz EM, Hill V, McCrone JT, Price A, Jorgensen D, O'Toole A, et al. (4 August 2020). "Evaluating the effects of SARS-CoV-2 Spike mutation D614G on transmissibility and pathogenicity". *Cell*. **184** (1): 64–75.e11. doi:10.1016/j.cell.2020.11.020. hdl:10044/1/84079. PMC 7674007. PMID 33275900.
306. Butowt R, Bilinska K, Von Bartheld CS (October 2020). "Chemosensory Dysfunction in COVID-19: Integration of Genetic and Epidemiological Data Points to D614G Spike Protein Variant as a Contributing Factor". *ACS Chemical Neuroscience*. **11** (20): 3180–3184. doi:10.1021/acschemneuro.0c00596. PMC 7581292. PMID 32997488.
307. Hodcroft EB, Domman DB, Snyder DJ, Oguntuyo KY, Van Diest M, Densmore KH, et al. (21 February 2021). "Emergence in late 2020 of multiple lineages of SARS-CoV-2 Spike protein variants affecting amino acid position 677". medRxiv 10.1101/2021.02.12.21251658.
308. "Study finds 7 newly-identified COVID-19 variants circulating in the United States". *ABC11 Raleigh-Durham*. 15 February 2021. Archived from the original on 3 September 2021. Retrieved 3 September 2021.
309. "Study shows P681H mutation is becoming globally prevalent among SARS-CoV-2 sequences". *News-Medical.net*. 10 January 2021. Archived from the original on 14 February 2021. Retrieved 11 February 2021.
310. "Malaysia identifies new Covid-19 strain, similar to one found in 3 other countries". *The Straits Times*. 23 December 2020. Archived from the original on 23 December 2020. Retrieved 10 January 2021. Tan Sri Dr Noor Hisham Abdullah, said it is still unknown whether the strain – dubbed the "A701B" mutation – is more infectious than usual
311. "Duterte says Sulu seeking help after new COVID-19 variant detected in nearby Sabah, Malaysia". *GMA News*. 27 December 2020. Archived from the original on 3 January 2021. Retrieved 10 January 2021.
312. "The current situation and Information on the Spike protein mutation of Covid-19 in Malaysia". *Kementerian Kesihatan Malaysia – Covid-19 Malaysia*. 25 December 2020. Archived from the original on 2 July 2021. Retrieved 15 January 2021.
313. "COVID-19 A701V mutation spreads to third wave clusters". *focusmalaysia.my*. 25 December 2020. Archived from the original on 14 May 2021. Retrieved 13 May 2021.
314. "Variants of Concerns (VOC), B.1.524, B.1.525, South African B.1.351, STRAIN D614G, A701V, B1.1.7". *covid-19.moh.gov.my*. 14 April 2021. Archived from the original on 2 July 2021. Retrieved 15 May 2021.
315. Yurkovetskiy L, Wang X, Pascal KE, Tomkins-Tinch C, Nyalile TP, Wang Y, et al. (October 2020). "Structural and Functional Analysis of the D614G SARS-CoV-2 Spike Protein Variant". *Cell*. **183** (3): 739–751.e8. doi:10.1016/j.cell.2020.09.032. PMC 7492024. PMID 32991842.
316. Thomson EC, Rosen LE, Shepherd JG, Spreafico R, da Silva Filipe A, Wojcechowskyj JA, et al. (March 2021). "Circulating SARS-CoV-2 spike N439K variants maintain fitness while evading antibody-mediated immunity". *Cell*. **184** (5): 1171–1187.e20. doi:10.1016/j.cell.2021.01.037. PMC 7843029. PMID 33621484.
317. Smout A (26 January 2021). "Britain to help other countries track down coronavirus variants". *Reuters*. Archived from the original on 26 January 2021. Retrieved 27 January 2021.
318. Donnelly L (26 January 2021). "UK to help sequence mutations of Covid around world to find dangerous new variants". *The Telegraph*. Archived from the original on 27 January 2021. Retrieved 28 January 2021.
319. Galani A, Aalizadeh R, Kostakis M, Markou A, Alygizakis N, Lytras T, et al. (January 2022). "SARS-CoV-2 wastewater surveillance data can predict hospitalizations and ICU admissions". *Science of the Total Environment*. **804**: 150151. Bibcode:2022ScTEn.80450151G. doi:10.1016/j.scitotenv.2021.150151. PMC 8421077. PMID 34623953.
320. Baaijens JA, Zulli A, Ott IM, Petrone ME, Alpert T, Fauver JR, et al. (2 September 2021). "Variant abundance estimation for SARS-CoV-2 in wastewater using RNA-Seq quantification". medRxiv 10.1101/2021.08.31.21262938.
321. Heijnen L, Elsinga G, Graaf Md, Molenkamp R, Koopmans MP, Medema G (26 March 2021). "Droplet Digital RT-PCR to detect SARS-CoV-2 variants of concern in wastewater". medRxiv 10.1101/2021.03.25.21254324v1.
322. *Methods for the detection and identification of SARS-CoV-2 variants*. *European Centre for Disease Prevention and Control, World Health Organization* (Technical report). Stockholm: European Centre for Disease Prevention and Control. 3 March 2021. Diagnostic screening assays of known VOCs.
323. *SARS-CoV-2 variants of concern and variants under investigation in England, technical briefing 15* (PDF) (Briefing). Public Health England. 11 June 2021. GOV-8576. Archived (PDF) from the original on 4 July 2021. Retrieved 15 June 2021.
324. *Assessment of the further emergence and potential impact of the SARS-CoV-2 Omicron variant of concern in the context of ongoing transmission of the Delta variant of concern in the EU/EEA, 18th update* (Technical report). Stockholm: European Centre for Disease Prevention and Control. 15 December 2021. Annexes 1 and 2.
325. Green ST, Cladi L (26 January 2021). "Covid-19 and evolutionary pressure – can we predict which genetic dangers lurk beyond the horizon?". *BMJ*: n230. Archived from the original on 8 June 2021. Retrieved 8 June 2021.
326. Jacobs A (2 November 2021). "Widespread Coronavirus Infection Found in Iowa Deer, New Study Says". *The New York Times*. Archived from the original on 28 December 2021. Retrieved 12 December 2021. Researchers and outside experts characterized the study's findings as a troubling development in the course of the pandemic. Widespread infection among North America's most ubiquitous game species could make eradicating the pathogen even more difficult, especially if they became a reservoir for mutations that eventually spilled back over to humans. \[...\] they are alerting deer hunters and others who handle deer to take precautions to avoid transmission. \[...\] If the virus were to become endemic in wild animals like deer, it could evolve over time to become more virulent and then infect people with a new strain capable of evading the current crop of vaccines.
327. Lassaunière R, Fonager J, Rasmussen M, Frische A, Strandh C, Rasmussen T, et al. (10 November 2020). *SARS-CoV-2 spike mutations arising in Danish mink, their spread to humans and neutralization data* (Preprint). Statens Serum Institut. Archived from the original on 10 November 2020. Retrieved 11 November 2020.
328. "Detection of new SARS-CoV-2 variants related to mink" (PDF). *ECDC.eu*. European Centre for Disease Prevention and Control. 12 November 2020. Archived (PDF) from the original on 8 January 2021. Retrieved 12 November 2020.
329. "SARS-CoV-2 mink-associated variant strain – Denmark". *WHO Disease Outbreak News*. 6 November 2020. Archived from the original on 12 November 2020. Retrieved 19 March 2021.
330. Kevany S, Carstensen T (19 November 2020). "Danish Covid mink variant 'very likely extinct', but controversial cull continues". *The Guardian*. Archived from the original on 24 April 2021. Retrieved 19 April 2021.
331. Larsen HD, Fonager J, Lomholt FK, Dalby T, Benedetti G, Kristensen B, et al. (February 2021). "Preliminary report of an outbreak of SARS-CoV-2 in mink and mink farmers associated with community spread, Denmark, June to November 2020". *Euro Surveillance*. **26** (5). doi:10.2807/1560-7917.ES.2021.26.5.210009. PMC 7863232. PMID 33541485.
332. Burioni R, Topol EJ (June 2021). "Has SARS-CoV-2 reached peak fitness?". *Nature Medicine*. **27** (8): 1323–24. doi:10.1038/s41591-021-01421-7. PMID 34155413.
333. Office of the Commissioner (23 February 2021). "Coronavirus (COVID-19) Update: FDA Issues Policies to Guide Medical Product Developers Addressing Virus Variants". *U.S. Food and Drug Administration (FDA)*. Retrieved 7 March 2021.
334. Rella SA, Kulikova YA, Dermitzakis ET, Kondrashov FA (30 July 2021). "Rates of SARS-CoV-2 transmission and vaccination impact the fate of vaccine-resistant strains". *Scientific Reports*. **11** (1): 15729. doi:10.1038/s41598-021-95025-3. ISSN 2045-2322. PMC 8324827. PMID 34330988.
335. Wang R, Chen J, Wei GW (December 2021). "Mechanisms of SARS-CoV-2 Evolution Revealing Vaccine-Resistant Mutations in Europe and America" (PDF). *The Journal of Physical Chemistry Letters*. **12** (49): 11850–11857. doi:10.1021/acs.jpclett.1c03380. PMC 8672435. PMID 34873910. Archived (PDF) from the original on 18 December 2021. Retrieved 27 January 2022.
336. "Study findings suggest spread of Omicron can be ascribed to immune evasiveness rather than an increase in transmissibility". *News-Medical.net*. 5 January 2022. Archived from the original on 21 January 2022. Retrieved 17 January 2022.
337. Cao Y, Wang J, Jian F, Xiao T, Song W, Yisimayi A, et al. (February 2022). "Omicron escapes the majority of existing SARS-CoV-2 neutralizing antibodies". *Nature*. **602** (7898): 657–663. doi:10.1038/d41586-021-03796-6. PMC 8866119. PMID 35016194. S2CID 245455422.
338. Liu L, Iketani S, Guo Y, Chan JF, Wang M, Liu L, et al. (February 2022). "Striking antibody evasion manifested by the Omicron variant of SARS-CoV-2". *Nature*. **602** (7898): 676–681. doi:10.1038/d41586-021-03826-3. PMID 35016198. S2CID 245462866.
339. Mohsin M, Mahmud S (May 2022). "Omicron SARS-CoV-2 variant of concern: A review on its transmissibility, immune evasion, reinfection, and severity". *Medicine*. **101** (19): e29165. doi:10.1097/MD.0000000000029165. PMC 9276130. PMID 35583528. S2CID 248858919.
340. "How soon after catching COVID-19 can you get it again?". *ABC News*. 2 May 2022. Archived from the original on 9 July 2022. Retrieved 24 June 2022.
341. "Omicron Variant: What You Need to Know". *Centers for Disease Control and Prevention*. 20 December 2021. Archived from the original on 27 January 2022. Retrieved 27 January 2022.
342. Shin DH, Smith DM, Choi JY (2022). "SARS-CoV-2 Omicron Variant of Concern: Everything You Wanted to Know about Omicron but Were Afraid to Ask". *Yonsei Medical Journal*. **63** (11): 977–983. doi:10.3349/ymj.2022.0383. PMC 9629902. PMID 36303305.
343. "COVID-19 Vaccine Boosters". U.S. Food and Drug Administration (FDA). 27 September 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
344. "Moderna COVID-19 Vaccines". *U.S. Food and Drug Administration (FDA)*. 7 October 2022. Archived from the original on 7 October 2022. Retrieved 8 October 2022.
345. "Pfizer-BioNTech COVID-19 Vaccines". *U.S. Food and Drug Administration (FDA)*. 3 October 2022. Archived from the original on 8 October 2022. Retrieved 8 October 2022.
346. "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2023". *U.S. Food and Drug Administration (FDA)*. 15 June 2023. Archived from the original on 17 June 2023. Retrieved 16 June 2023.  This article incorporates text from this source, which is in the public domain.
347. Recommendation for the 2023-2024 Formula of COVID-19 vaccines in the U.S. (PDF) (Report). U.S. Food and Drug Administration (FDA). 16 June 2023. Archived from the original on 16 June 2023. Retrieved 16 June 2023.
348. "Updated COVID-19 Vaccines for Use in the United States Beginning in Fall 2024". *U.S. Food and Drug Administration (FDA)*. 5 June 2024. Archived from the original on 18 June 2024. Retrieved 19 June 2024.  This article incorporates text from this source, which is in the public domain.

## Further reading